mmol mol	0	1.7067	7	Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol  percent in	HbA1c is 75 mmol mol  percent or higher), administered either: separately or as a pre-mixed (biphasic) human insulin preparation.	Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol  percent in	HbA1c is 75 mmol mol  percent or higher), administered either: separately or as a pre-mixed (biphasic) human insulin preparation.	For adults with type 2 diabetes managed either by lifestyle and diet, or by lifestyle and diet combined with a single drug not associated with hypoglycaemia, support the person to aim for an HbA1c level of 48 mmol mol ( percent)	For adults on a drug associated with hypoglycaemia, support the person to aim for an HbA1c level of 53 mmol mol ( percent).	In adults with type 2 diabetes, if HbA1c levels are not adequately controlled by a single drug and rise to 58 mmol mol ( percent) or higher: reinforce advice about diet, lifestyle and adherence to drug treatment and support the person to aim for an HbA1c level of 53 mmol mol ( percent) and intensify drug treatment.	
drug treatment(s)	0	1.6525	2	Base the choice of drug treatment(s) on: the effectiveness of the drug treatment(s) in terms of metabolic response	Last updated May 2017 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost).	
non-insulin blood	0	1.6525	3	Treatment with a single non-insulin blood glucose lowering therapy (monotherapy)	Treatment with 2 non-insulin blood glucose lowering therapies in combination (dual therapy)	Treatment with either 3 non-insulin blood glucose lowering therapies in combination (triple therapy) or any treatment combination containing insulin	
treatment treatment	1	1.6525	0	
combination therapy	0	1.6138	4	Treatment with combinations of medicines including sodium–glucose cotransporter 2 (SGLT-2) inhibitors , may be appropriate for some people with type 2 diabetes; see the NICE guidance on canagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in combination therapy for treating type 2 diabetes and empagliflozin in combination therapy for treating type 2 diabetes.	If triple therapy with metformin and 2 other oral drugs (see recommendation ) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities.	Treatment with combinations of medicines including SGLT-2 inhibitors , may be appropriate for some people with type 2 diabetes; see the NICE guidance on canagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in triple therapy for treating type 2 diabetes and empagliflozin in combination therapy for treating type 2 diabetes.	Treatment with combinations of medicines including SGLT-2 inhibitors , may be appropriate for some people with type 2 diabetes; see the NICE guidance on canagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in combination therapy for treating type 2 diabetes and empagliflozin in combination therapy for treating type 2 diabetes.	
heart failure	0	1.5779	6	Pioglitazone is associated with an increased risk of heart failure, bladder cancer and bone fracture	Pioglitazone is associated with an increased risk of heart failure, bladder cancer and bone fracture	Pioglitazone is associated with an increased risk of heart failure, bladder cancer and bone fracture	Pioglitazone is associated with an increased risk of heart failure, bladder cancer and bone fracture	In adults with type 2 diabetes, do not offer or continue pioglitazone if they have any of the following: heart failure or history of heart failure	It advises that if the combination is used, people should be observed for signs and symptoms of heart failure, weight gain, and oedema	
cardiovascular disease	0	1.5453	3	Do not offer antiplatelet therapy (aspirin or clopidogrel) for adults with type 2 diabetes without cardiovascular disease.	For guidance on the primary and secondary prevention of cardiovascular disease in adults with type 2 diabetes, see the NICE guidelines on cardiovascular disease and myocardial infarction.	Assess, educate and support men with type 2 diabetes who have problematic erectile dysfunction, addressing contributory factors such as cardiovascular disease as well as possible treatment options.	
3–6 months	0	1.5204	2	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) advises that 'prescribers should review the safety and efficacy of pioglitazone in individuals after 3–6 months of treatment to ensure that only patients who are deriving benefit continue to be treated'.	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) advises that 'prescribers should review the safety and efficacy of pioglitazone in individuals after 3–6 months of treatment to ensure that only patients who are deriving benefit continue to be treated'.	
bariatric surgery	0	1.5204	3	Dietary advice and bariatric surgery	Dietary advice and bariatric surgery	For recommendations on bariatric surgery for people with recent-onset type 2 diabetes, see the section on bariatric surgery for people with recent-onset type 2 diabetes in the NICE guideline on obesity.	
details medicines	0	1.5204	0	
dose titration	0	1.5204	1	When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding	
eye screening	0	1.5204	7	Arrange repeat structured eye screening annually. 2009, amended 2016	Perform visual acuity testing as a routine part of eye screening programmes.	Arrange repeat structured eye screening annually. 2009, amended 2016	Perform visual acuity testing as a routine part of eye screening programmes.	On diagnosis, GPs should immediately refer adults with type 2 diabetes to the local eye screening service	Explain the reasons for, and success of, eye screening systems to adults with type 2 diabetes, so that attendance is not reduced by lack of knowledge or fear of outcome.	Depending on the findings, follow structured eye screening by: routine review in 1 year or earlier review or referral to an ophthalmologist.	
foot problems	0	1.5204	3	Diabetic foot problems	Diabetic foot problems	For guidance on preventing and managing foot problems in adults with type 2 diabetes, see the NICE guideline on diabetic foot problems.	
insulin delivery	0	1.5204	3	Insulin delivery	Insulin delivery	For guidance on insulin delivery for adults with type 2 diabetes, see the insulin delivery section in the NICE guideline on type 1 diabetes.	
kidney disease	1	1.5204	4	Diabetic kidney disease	Diabetic kidney disease	For guidance on managing kidney disease in adults with type 2 diabetes, see the	NICE guideline on chronic kidney disease in adults.	
minute m2	0	1.5204	4	Stop metformin if the eGFR is below 30 ml minute m2.	Stop metformin if the eGFR is below 30 ml minute m2.	In adults with type 2 diabetes, review the dose of metformin if the estimated glomerular filtration rate (eGFR) is below 45 ml minute m2:	Prescribe metformin with caution for those at risk of a sudden deterioration in kidney function and those at risk of eGFR falling below 45 ml minute m2.	
ml minute	0	1.5204	4	Stop metformin if the eGFR is below 30 ml minute m2.	Stop metformin if the eGFR is below 30 ml minute m2.	In adults with type 2 diabetes, review the dose of metformin if the estimated glomerular filtration rate (eGFR) is below 45 ml minute m2:	Prescribe metformin with caution for those at risk of a sudden deterioration in kidney function and those at risk of eGFR falling below 45 ml minute m2.	
product characteristics	0	1.5204	4	MHRA guidance and summaries of product characteristics	MHRA guidance and summaries of product characteristics	Known risk factors for these conditions, including increased age, should be carefully evaluated before treatment: see the manufacturers' summaries of product characteristics for details	Known risk factors for these conditions, including increased age, should be carefully evaluated before treatment: see the manufacturers' summaries of product characteristics for details	
recent-onset type	0	1.5204	1	For recommendations on bariatric surgery for people with recent-onset type 2 diabetes, see the section on bariatric surgery for people with recent-onset type 2 diabetes in the NICE guideline on obesity.	
risk factors	0	1.5204	4	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) notes that cases of cardiac failure have been reported when pioglitazone was used in combination with insulin, especially in patients with risk factors for the development of cardiac failure	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) notes that cases of cardiac failure have been reported when pioglitazone was used in combination with insulin, especially in patients with risk factors for the development of cardiac failure	Known risk factors for these conditions, including increased age, should be carefully evaluated before treatment: see the manufacturers' summaries of product characteristics for details	Known risk factors for these conditions, including increased age, should be carefully evaluated before treatment: see the manufacturers' summaries of product characteristics for details	
sglt-2 inhibitor	0	1.5204	4	Treatment with combinations of medicines including SGLT-2 inhibitors , may be appropriate for some people with type 2 diabetes; see the NICE guidance on canagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in triple therapy for treating type 2 diabetes and empagliflozin in combination therapy for treating type 2 diabetes.	Treatment with combinations of medicines including SGLT-2 inhibitors , may be appropriate for some people with type 2 diabetes; see the NICE guidance on canagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in combination therapy for treating type 2 diabetes and empagliflozin in combination therapy for treating type 2 diabetes.	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2016) warned that serious, life-threatening, and fatal cases of diabetic ketoacidosis have been reported rarely in people taking an SGLT-2 inhibitor (a substantial proportion of the cases concerned off-label use in people with type 1 diabetes, which is not recommended)	The MHRA advised that healthcare professionals should test for raised ketones in people with ketoacidosis symptoms who are receiving an SGLT-2 inhibitor, even if their plasma glucose levels are near-normal.	
blood pressure	0	1.5073	15	Blood pressure management	Add medications if lifestyle advice does not reduce blood pressure to below 140 80 mmHg (below 130 80 mmHg if there is kidney, eye or cerebrovascular damage).	If the person's blood pressure is not reduced to the individually agreed target with first-line therapy, add a calcium-channel blocker or a diuretic (usually a thiazide or thiazide-related diuretic)	If the person's blood pressure is not reduced to the individually agreed target with triple therapy, add an alpha-blocker, a beta-blocker or a potassium-sparing diuretic (the last with caution if the person is already taking an ACE inhibitor or an angiotensin II-receptor antagonist).	Monitor the blood pressure of a person who has attained and consistently remained at his or her blood pressure target every 4–6 months	Blood pressure management	Add medications if lifestyle advice does not reduce blood pressure to below 140 80 mmHg (below 130 80 mmHg if there is kidney, eye or cerebrovascular damage).	If the person's blood pressure is not reduced to the individually agreed target with first-line therapy, add a calcium-channel blocker or a diuretic (usually a thiazide or thiazide-related diuretic)	If the person's blood pressure is not reduced to the individually agreed target with triple therapy, add an alpha-blocker, a beta-blocker or a potassium-sparing diuretic (the last with caution if the person is already taking an ACE inhibitor or an angiotensin II-receptor antagonist).	Monitor the blood pressure of a person who has attained and consistently remained at his or her blood pressure target every 4–6 months	Measure blood pressure at least annually in an adult with type 2 diabetes without previously diagnosed hypertension or renal disease	For an adult with type 2 diabetes on antihypertensive drug treatment when diabetes is diagnosed, review blood pressure control and medications used.	Repeat blood pressure measurements within: 1 month if blood pressure is higher than 150 90 mmHg 2 months if blood pressure is higher than 140 80 mmHg 2 months if blood pressure is higher than 130 80 mmHg and there is kidney, eye or cerebrovascular damage.	Monitor blood pressure every 1–2 months, and intensify therapy if the person is already on antihypertensive drug treatment, until the blood pressure is consistently below 140 80 mmHg (below 130 80 mmHg if there is kidney, eye or cerebrovascular damage).	Check for possible adverse effects of antihypertensive drug treatment – including the risks from unnecessarily low blood pressure.	
autonomic neuropathy	0	1.4936	5	Autonomic neuropathy	Think about the possibility of autonomic neuropathy affecting the gut in adults with type 2 diabetes who have unexplained diarrhoea that happens particularly at night 2009, amended 2015	When using tricyclic drugs and antihypertensive drug treatments in adults with type 2 diabetes who have autonomic neuropathy, be aware of the increased likelihood of side effects such as orthostatic hypotension.	Investigate the possibility of autonomic neuropathy affecting the bladder in adults with type 2 diabetes who have unexplained bladder-emptying problems.	In managing autonomic neuropathy symptoms, include specific interventions indicated by the manifestations (for example, for abnormal sweating or nocturnal diarrhoea).	
dipeptidyl peptidase-4	0	1.457	2	Recommendations in this section that cover dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) mimetics and sulfonylureas refer to each of these groups of drugs at a class level.	In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, consider initial drug treatment with: a dipeptidyl peptidase-4 (DPP-4) inhibitor or pioglitazone or a sulfonylurea.	
phosphodiesterase-5 inhibitor	0	1.457	2	Consider a phosphodiesterase-5 inhibitor to treat problematic erectile dysfunction in men with type 2 diabetes, initially choosing the drug with the lowest acquisition cost and taking into account any contraindications.	Following discussion, refer men with type 2 diabetes to a service offering other medical, surgical or psychological management of erectile dysfunction if treatment (including a phosphodiesterase-5 inhibitor, as appropriate) has been unsuccessful.	
problematic erectile	0	1.457	2	Assess, educate and support men with type 2 diabetes who have problematic erectile dysfunction, addressing contributory factors such as cardiovascular disease as well as possible treatment options.	Consider a phosphodiesterase-5 inhibitor to treat problematic erectile dysfunction in men with type 2 diabetes, initially choosing the drug with the lowest acquisition cost and taking into account any contraindications.	
erectile dysfunction	0	1.4038	6	Erectile dysfunction	Erectile dysfunction	Offer men with type 2 diabetes the opportunity to discuss erectile dysfunction as part of their annual review.	Assess, educate and support men with type 2 diabetes who have problematic erectile dysfunction, addressing contributory factors such as cardiovascular disease as well as possible treatment options.	Consider a phosphodiesterase-5 inhibitor to treat problematic erectile dysfunction in men with type 2 diabetes, initially choosing the drug with the lowest acquisition cost and taking into account any contraindications.	Following discussion, refer men with type 2 diabetes to a service offering other medical, surgical or psychological management of erectile dysfunction if treatment (including a phosphodiesterase-5 inhibitor, as appropriate) has been unsuccessful.	
first-line antihypertensive	0	1.3986	3	First-line antihypertensive drug treatment should be a once-daily, generic angiotensin-converting enzyme (ACE) inhibitor	The first-line antihypertensive drug treatment for a person of African or	A calcium-channel blocker should be the first-line antihypertensive drug treatment for a woman for whom, after an informed discussion, it is agreed there is a possibility of her becoming pregnant.	
review treatment	0	1.3986	3	Consider short-term self-monitoring of blood glucose levels in adults with type 2 diabetes (and review treatment as necessary): when starting treatment with oral or intravenous corticosteroids or to confirm suspected hypoglycaemia.	Review treatment as necessary.	If an adult with type 2 diabetes is symptomatically hyperglycaemic, consider insulin (see recommendations – ) or a sulfonylurea, and review treatment when blood glucose control has been achieved.	
ace inhibitor	0	1.3919	6	For a person with continuing intolerance to an ACE inhibitor (other than renal deterioration or hyperkalaemia), substitute an angiotensin II-receptor antagonist for the ACE inhibitor.	If the person's blood pressure is not reduced to the individually agreed target with triple therapy, add an alpha-blocker, a beta-blocker or a potassium-sparing diuretic (the last with caution if the person is already taking an ACE inhibitor or an angiotensin II-receptor antagonist).	For a person with continuing intolerance to an ACE inhibitor (other than renal deterioration or hyperkalaemia), substitute an angiotensin II-receptor antagonist for the ACE inhibitor.	If the person's blood pressure is not reduced to the individually agreed target with triple therapy, add an alpha-blocker, a beta-blocker or a potassium-sparing diuretic (the last with caution if the person is already taking an ACE inhibitor or an angiotensin II-receptor antagonist).	Caribbean family origin should be an ACE inhibitor plus either a diuretic or a generic calcium-channel blocker.	Do not combine an ACE inhibitor with an angiotensin II-receptor antagonist to treat hypertension.	
calcium-channel blocker	0	1.3919	6	If the person's blood pressure is not reduced to the individually agreed target with first-line therapy, add a calcium-channel blocker or a diuretic (usually a thiazide or thiazide-related diuretic)	Add the other drug (that is, the calcium-channel blocker or diuretic) if the target is not reached with dual therapy 2009, amended 2015	If the person's blood pressure is not reduced to the individually agreed target with first-line therapy, add a calcium-channel blocker or a diuretic (usually a thiazide or thiazide-related diuretic)	Add the other drug (that is, the calcium-channel blocker or diuretic) if the target is not reached with dual therapy 2009, amended 2015	Caribbean family origin should be an ACE inhibitor plus either a diuretic or a generic calcium-channel blocker.	A calcium-channel blocker should be the first-line antihypertensive drug treatment for a woman for whom, after an informed discussion, it is agreed there is a possibility of her becoming pregnant.	
caribbean family	0	1.3919	2	African or Caribbean family origin, or women for whom there is a possibility of becoming pregnant.	Caribbean family origin should be an ACE inhibitor plus either a diuretic or a generic calcium-channel blocker.	
family origin	0	1.3919	2	African or Caribbean family origin, or women for whom there is a possibility of becoming pregnant.	Caribbean family origin should be an ACE inhibitor plus either a diuretic or a generic calcium-channel blocker.	
gastrointestinal side	0	1.3919	2	Gradually increase the dose of standard-release metformin over several weeks to minimise the risk of gastrointestinal side effects in adults with type 2 diabetes.	If an adult with type 2 diabetes experiences gastrointestinal side effects with standard-release metformin, consider a trial of modified-release metformin.	
insulin-based treatment	0	1.3188	3	In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation ) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations – ).	In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, and if dual therapy with 2 oral drugs (see recommendation ) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider insulin-based treatment (see recommendations – ).	Insulin-based treatments	
standard-release metformin	0	1.3129	3	Offer standard-release metformin as the initial drug treatment for adults with type 2 diabetes.	Gradually increase the dose of standard-release metformin over several weeks to minimise the risk of gastrointestinal side effects in adults with type 2 diabetes.	If an adult with type 2 diabetes experiences gastrointestinal side effects with standard-release metformin, consider a trial of modified-release metformin.	
side effects	0	1.2901	5	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2014) notes that domperidone is associated with a small increased risk of serious cardiac side effects	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2014) notes that domperidone is associated with a small increased risk of serious cardiac side effects	Gradually increase the dose of standard-release metformin over several weeks to minimise the risk of gastrointestinal side effects in adults with type 2 diabetes.	If an adult with type 2 diabetes experiences gastrointestinal side effects with standard-release metformin, consider a trial of modified-release metformin.	When using tricyclic drugs and antihypertensive drug treatments in adults with type 2 diabetes who have autonomic neuropathy, be aware of the increased likelihood of side effects such as orthostatic hypotension.	
dpp-4 inhibitor	0	1.2564	3	In adults with type 2 diabetes, if initial drug treatment with metformin has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider dual therapy with: metformin and a DPP-4 inhibitor or metformin and pioglitazone or metformin and a sulfonylurea.	In adults with type 2 diabetes, if metformin is contraindicated or not tolerated and initial drug treatment has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider dual therapy with: a DPP-4 inhibitor and pioglitazone or a DPP-4 inhibitor and a sulfonylurea or pioglitazone and a sulfonylurea.	In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation ) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations – ).	
5–10percent individualise	0	1.2263	0	
acute intercurrent	0	1.2263	1	Be aware that adults with type 2 diabetes who have acute intercurrent illness are at risk of worsening hyperglycaemia	
advise adults	0	1.2263	1	Advise adults with type 2 diabetes that limited substitution of sucrose-containing foods for other carbohydrate in the meal plan is allowable, but that they should take care to avoid excess energy intake.	
alcohol intake	0	1.2263	1	Individualise recommendations for carbohydrate and alcohol intake, and meal patterns	
angiotensin ii-receptor	0	1.2263	5	For a person with continuing intolerance to an ACE inhibitor (other than renal deterioration or hyperkalaemia), substitute an angiotensin II-receptor antagonist for the ACE inhibitor.	If the person's blood pressure is not reduced to the individually agreed target with triple therapy, add an alpha-blocker, a beta-blocker or a potassium-sparing diuretic (the last with caution if the person is already taking an ACE inhibitor or an angiotensin II-receptor antagonist).	For a person with continuing intolerance to an ACE inhibitor (other than renal deterioration or hyperkalaemia), substitute an angiotensin II-receptor antagonist for the ACE inhibitor.	If the person's blood pressure is not reduced to the individually agreed target with triple therapy, add an alpha-blocker, a beta-blocker or a potassium-sparing diuretic (the last with caution if the person is already taking an ACE inhibitor or an angiotensin II-receptor antagonist).	Do not combine an ACE inhibitor with an angiotensin II-receptor antagonist to treat hypertension.	
angiotensin-converting enzyme	0	1.2263	1	First-line antihypertensive drug treatment should be a once-daily, generic angiotensin-converting enzyme (ACE) inhibitor	
annual review	0	1.2263	1	Offer men with type 2 diabetes the opportunity to discuss erectile dysfunction as part of their annual review.	
antiplatelet therapy	0	1.2263	3	Antiplatelet therapy	Antiplatelet therapy	Do not offer antiplatelet therapy (aspirin or clopidogrel) for adults with type 2 diabetes without cardiovascular disease.	
arrange emergency	0	1.2263	1	Arrange emergency review by an ophthalmologist for: sudden loss of vision rubeosis iridis pre-retinal or vitreous haemorrhage retinal detachment.	
arrange rapid	0	1.2263	1	Arrange rapid review by an ophthalmologist for new vessel formation.	
biosimilar product(s)	0	1.2263	1	The recommendations in this guideline also apply to any current and future biosimilar product(s) of insulin glargine that have an appropriate marketing authorisation that allows the use of the biosimilar(s) in the same indication.	
bladder-emptying problems	0	1.2263	1	Investigate the possibility of autonomic neuropathy affecting the bladder in adults with type 2 diabetes who have unexplained bladder-emptying problems.	
body weight	0	1.2263	3	HbA1c and a weight loss of at least 3percent of initial body weight in 6 months).	HbA1c and a weight loss of at least 3percent of initial body weight in 6 months).	For adults with type 2 diabetes who are overweight, set an initial body weight loss target of 5–10percent	
carbohydrate content	0	1.2263	1	When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks.	
cardiac status	0	1.2263	1	Pioglitazone should be discontinued if any deterioration in cardiac status occurs.	
care advice	0	1.2263	1	In adults with type 2 diabetes, only offer a GLP-1 mimetic in combination with insulin with specialist care advice and ongoing support from a consultant-led multidisciplinary team .	
class level	0	1.2263	1	Recommendations in this section that cover dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) mimetics and sulfonylureas refer to each of these groups of drugs at a class level.	
consultant-led multidisciplinary	0	1.2263	3	A consultant-led multidisciplinary team may include a wide range of staff based in primary, secondary and community care.	A consultant-led multidisciplinary team may include a wide range of staff based in primary, secondary and community care.	In adults with type 2 diabetes, only offer a GLP-1 mimetic in combination with insulin with specialist care advice and ongoing support from a consultant-led multidisciplinary team .	
contributory factors	0	1.2263	1	Assess, educate and support men with type 2 diabetes who have problematic erectile dysfunction, addressing contributory factors such as cardiovascular disease as well as possible treatment options.	
contributory sympathetic	0	1.2263	1	Think about the possibility of contributory sympathetic nervous system damage for adults with type 2 diabetes who lose the warning signs of hypoglycaemia. 2009, amended 2015	
current drug	0	1.2263	1	Make changes only if there is poor control or if current drug treatment is not appropriate because of microvascular complications or metabolic problems.	
diabetic peripheral	0	1.2263	1	For guidance on managing painful diabetic peripheral neuropathy in adults with type 2 diabetes, see the NICE guideline on neuropathic pain in adults.	
dietary advice	0	1.2263	5	Dietary advice and bariatric surgery	Integrate dietary advice with a personalised diabetes management plan, including other aspects of lifestyle modification, such as increasing physical activity and losing weight.	Dietary advice and bariatric surgery	Integrate dietary advice with a personalised diabetes management plan, including other aspects of lifestyle modification, such as increasing physical activity and losing weight.	Provide dietary advice in a form sensitive to the person's needs, culture and beliefs, being sensitive to their willingness to change and the effects on their quality of life.	
differential diagnosis	0	1.2263	1	If gastroparesis is suspected, consider referral to specialist services if: the differential diagnosis is in doubt or persistent or severe vomiting occurs.	
disease offer	0	1.2263	0	
education programme	0	1.2263	7	Offer group education programmes as the preferred option	Ensure that the patient-education programmes available meet the cultural, linguistic, cognitive and literacy needs within the local area.	Offer group education programmes as the preferred option	Ensure that the patient-education programmes available meet the cultural, linguistic, cognitive and literacy needs within the local area.	Ensure that any structured education programme for adults with type 2 diabetes includes the following components:	Ensure the patient-education programme provides the necessary resources to support the educators, and that educators are properly trained and given time to develop and maintain their skills.	Ensure that all members of the diabetes healthcare team are familiar with the patient-education programmes available locally, that these programmes are integrated with the rest of the care pathway, and that adults with type 2 diabetes and their family members or carers (as appropriate) have the opportunity to contribute to the design and provision of local programmes.	
emergency review	0	1.2263	1	Arrange emergency review by an ophthalmologist for: sudden loss of vision rubeosis iridis pre-retinal or vitreous haemorrhage retinal detachment.	
energy intake	0	1.2263	1	Advise adults with type 2 diabetes that limited substitution of sucrose-containing foods for other carbohydrate in the meal plan is allowable, but that they should take care to avoid excess energy intake.	
equal standard	0	1.2263	1	Provide an alternative of equal standard for a person unable or unwilling to participate in group education.	
excess energy	0	1.2263	1	Advise adults with type 2 diabetes that limited substitution of sucrose-containing foods for other carbohydrate in the meal plan is allowable, but that they should take care to avoid excess energy intake.	
form sensitive	0	1.2263	1	Provide dietary advice in a form sensitive to the person's needs, culture and beliefs, being sensitive to their willingness to change and the effects on their quality of life.	
future biosimilar	0	1.2263	1	The recommendations in this guideline also apply to any current and future biosimilar product(s) of insulin glargine that have an appropriate marketing authorisation that allows the use of the biosimilar(s) in the same indication.	
generic angiotensin-converting	0	1.2263	1	First-line antihypertensive drug treatment should be a once-daily, generic angiotensin-converting enzyme (ACE) inhibitor	
generic calcium-channel	0	1.2263	1	Caribbean family origin should be an ACE inhibitor plus either a diuretic or a generic calcium-channel blocker.	
glp-1 mimetic	0	1.2263	3	Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol  percent in	Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol  percent in	In adults with type 2 diabetes, only offer a GLP-1 mimetic in combination with insulin with specialist care advice and ongoing support from a consultant-led multidisciplinary team .	
group education	0	1.2263	3	Offer group education programmes as the preferred option	Offer group education programmes as the preferred option	Provide an alternative of equal standard for a person unable or unwilling to participate in group education.	
haemorrhage retinal	0	1.2263	1	Arrange emergency review by an ophthalmologist for: sudden loss of vision rubeosis iridis pre-retinal or vitreous haemorrhage retinal detachment.	
hba1c targets	0	1.2263	1	For guidance on HbA1c targets for women with type 2 diabetes who are pregnant or planning to become pregnant, see the NICE guideline on diabetes in pregnancy.	
hyperglycaemia review	0	1.2263	0	
ii-receptor antagonist	0	1.2263	5	For a person with continuing intolerance to an ACE inhibitor (other than renal deterioration or hyperkalaemia), substitute an angiotensin II-receptor antagonist for the ACE inhibitor.	If the person's blood pressure is not reduced to the individually agreed target with triple therapy, add an alpha-blocker, a beta-blocker or a potassium-sparing diuretic (the last with caution if the person is already taking an ACE inhibitor or an angiotensin II-receptor antagonist).	For a person with continuing intolerance to an ACE inhibitor (other than renal deterioration or hyperkalaemia), substitute an angiotensin II-receptor antagonist for the ACE inhibitor.	If the person's blood pressure is not reduced to the individually agreed target with triple therapy, add an alpha-blocker, a beta-blocker or a potassium-sparing diuretic (the last with caution if the person is already taking an ACE inhibitor or an angiotensin II-receptor antagonist).	Do not combine an ACE inhibitor with an angiotensin II-receptor antagonist to treat hypertension.	
independent assessors	0	1.2263	1	It is quality assured, and reviewed by trained, competent, independent assessors who measure it against criteria that ensure consistency.	
individualise recommendations	0	1.2263	1	Individualise recommendations for carbohydrate and alcohol intake, and meal patterns	
informed discussion	0	1.2263	1	A calcium-channel blocker should be the first-line antihypertensive drug treatment for a woman for whom, after an informed discussion, it is agreed there is a possibility of her becoming pregnant.	
inhibitor african	0	1.2263	0	
initial body	0	1.2263	3	HbA1c and a weight loss of at least 3percent of initial body weight in 6 months).	HbA1c and a weight loss of at least 3percent of initial body weight in 6 months).	For adults with type 2 diabetes who are overweight, set an initial body weight loss target of 5–10percent	
insulin secretagogue	0	1.2263	1	Reducing the risk of hypoglycaemia should be a particular aim for a person using insulin or an insulin secretagogue.	
intercurrent illness	0	1.2263	1	Be aware that adults with type 2 diabetes who have acute intercurrent illness are at risk of worsening hyperglycaemia	
intravenous corticosteroids	0	1.2263	1	Consider short-term self-monitoring of blood glucose levels in adults with type 2 diabetes (and review treatment as necessary): when starting treatment with oral or intravenous corticosteroids or to confirm suspected hypoglycaemia.	
iridis pre-retinal	0	1.2263	1	Arrange emergency review by an ophthalmologist for: sudden loss of vision rubeosis iridis pre-retinal or vitreous haemorrhage retinal detachment.	
limited substitution	0	1.2263	1	Advise adults with type 2 diabetes that limited substitution of sucrose-containing foods for other carbohydrate in the meal plan is allowable, but that they should take care to avoid excess energy intake.	
loss target	0	1.2263	1	For adults with type 2 diabetes who are overweight, set an initial body weight loss target of 5–10percent	
low blood	0	1.2263	1	Check for possible adverse effects of antihypertensive drug treatment – including the risks from unnecessarily low blood pressure.	
marketing authorisation	0	1.2263	3	Domperidone is now contraindicated in certain groups in whom the risk of cardiac effects is higher; its marketing authorisations have also been restricted to its use in the relief of nausea and vomiting only, at the lowest effective dose and for the shortest possible time (usually not more than 1 week): see the	Domperidone is now contraindicated in certain groups in whom the risk of cardiac effects is higher; its marketing authorisations have also been restricted to its use in the relief of nausea and vomiting only, at the lowest effective dose and for the shortest possible time (usually not more than 1 week): see the	The recommendations in this guideline also apply to any current and future biosimilar product(s) of insulin glargine that have an appropriate marketing authorisation that allows the use of the biosimilar(s) in the same indication.	
meal patterns	0	1.2263	1	Individualise recommendations for carbohydrate and alcohol intake, and meal patterns	
meal plan	0	1.2263	2	Advise adults with type 2 diabetes that limited substitution of sucrose-containing foods for other carbohydrate in the meal plan is allowable, but that they should take care to avoid excess energy intake.	When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks.	
meal planning	0	1.2263	1	When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks.	
measure blood	0	1.2263	1	Measure blood pressure at least annually in an adult with type 2 diabetes without previously diagnosed hypertension or renal disease	
metabolic problems	0	1.2263	1	Make changes only if there is poor control or if current drug treatment is not appropriate because of microvascular complications or metabolic problems.	
microvascular complications	0	1.2263	1	Make changes only if there is poor control or if current drug treatment is not appropriate because of microvascular complications or metabolic problems.	
modified-release metformin	0	1.2263	1	If an adult with type 2 diabetes experiences gastrointestinal side effects with standard-release metformin, consider a trial of modified-release metformin.	
multidisciplinary team	0	1.2263	3	A consultant-led multidisciplinary team may include a wide range of staff based in primary, secondary and community care.	A consultant-led multidisciplinary team may include a wide range of staff based in primary, secondary and community care.	In adults with type 2 diabetes, only offer a GLP-1 mimetic in combination with insulin with specialist care advice and ongoing support from a consultant-led multidisciplinary team .	
nervous system	0	1.2263	1	Think about the possibility of contributory sympathetic nervous system damage for adults with type 2 diabetes who lose the warning signs of hypoglycaemia. 2009, amended 2015	
neuropathic pain	0	1.2263	1	For guidance on managing painful diabetic peripheral neuropathy in adults with type 2 diabetes, see the NICE guideline on neuropathic pain in adults.	
neuropathy symptoms	0	1.2263	1	In managing autonomic neuropathy symptoms, include specific interventions indicated by the manifestations (for example, for abnormal sweating or nocturnal diarrhoea).	
nocturnal diarrhoea	0	1.2263	1	In managing autonomic neuropathy symptoms, include specific interventions indicated by the manifestations (for example, for abnormal sweating or nocturnal diarrhoea).	
nutritional advice	0	1.2263	1	Provide individualised and ongoing nutritional advice from a healthcare professional with specific expertise and competencies in nutrition.	
oedema pioglitazone	0	1.2263	0	
offer men	0	1.2263	1	Offer men with type 2 diabetes the opportunity to discuss erectile dysfunction as part of their annual review.	
ongoing nutritional	0	1.2263	1	Provide individualised and ongoing nutritional advice from a healthcare professional with specific expertise and competencies in nutrition.	
ongoing support	0	1.2263	1	In adults with type 2 diabetes, only offer a GLP-1 mimetic in combination with insulin with specialist care advice and ongoing support from a consultant-led multidisciplinary team .	
painful diabetic	0	1.2263	3	Painful diabetic neuropathy	Painful diabetic neuropathy	For guidance on managing painful diabetic peripheral neuropathy in adults with type 2 diabetes, see the NICE guideline on neuropathic pain in adults.	
peripheral neuropathy	0	1.2263	1	For guidance on managing painful diabetic peripheral neuropathy in adults with type 2 diabetes, see the NICE guideline on neuropathic pain in adults.	
person unable	0	1.2263	1	Provide an alternative of equal standard for a person unable or unwilling to participate in group education.	
planning system	0	1.2263	1	When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks.	
poor control	0	1.2263	1	Make changes only if there is poor control or if current drug treatment is not appropriate because of microvascular complications or metabolic problems.	
pressure control	0	1.2263	1	For an adult with type 2 diabetes on antihypertensive drug treatment when diabetes is diagnosed, review blood pressure control and medications used.	
preventive lifestyle	0	1.2263	1	Offer and reinforce preventive lifestyle advice.	
psychological management	0	1.2263	1	Following discussion, refer men with type 2 diabetes to a service offering other medical, surgical or psychological management of erectile dysfunction if treatment (including a phosphodiesterase-5 inhibitor, as appropriate) has been unsuccessful.	
rapid review	0	1.2263	1	Arrange rapid review by an ophthalmologist for new vessel formation.	
renal disease	0	1.2263	1	Measure blood pressure at least annually in an adult with type 2 diabetes without previously diagnosed hypertension or renal disease	
rescue therapy	0	1.2263	1	Rescue therapy at any phase of treatment	
retinal detachment	0	1.2263	1	Arrange emergency review by an ophthalmologist for: sudden loss of vision rubeosis iridis pre-retinal or vitreous haemorrhage retinal detachment.	
routine review	0	1.2263	1	Depending on the findings, follow structured eye screening by: routine review in 1 year or earlier review or referral to an ophthalmologist.	
rubeosis iridis	0	1.2263	1	Arrange emergency review by an ophthalmologist for: sudden loss of vision rubeosis iridis pre-retinal or vitreous haemorrhage retinal detachment.	
self-manage diabetes	0	1.2263	1	It has specific aims and learning objectives, and supports the person and their family members and carers in developing attitudes, beliefs, knowledge and skills to self-manage diabetes.	
severe vomiting	0	1.2263	1	If gastroparesis is suspected, consider referral to specialist services if: the differential diagnosis is in doubt or persistent or severe vomiting occurs.	
short-term self-monitoring	0	1.2263	1	Consider short-term self-monitoring of blood glucose levels in adults with type 2 diabetes (and review treatment as necessary): when starting treatment with oral or intravenous corticosteroids or to confirm suspected hypoglycaemia.	
specialist care	0	1.2263	1	In adults with type 2 diabetes, only offer a GLP-1 mimetic in combination with insulin with specialist care advice and ongoing support from a consultant-led multidisciplinary team .	
specialist services	0	1.2263	1	If gastroparesis is suspected, consider referral to specialist services if: the differential diagnosis is in doubt or persistent or severe vomiting occurs.	
specific aims	0	1.2263	1	It has specific aims and learning objectives, and supports the person and their family members and carers in developing attitudes, beliefs, knowledge and skills to self-manage diabetes.	
specific expertise	0	1.2263	1	Provide individualised and ongoing nutritional advice from a healthcare professional with specific expertise and competencies in nutrition.	
specific interventions	0	1.2263	1	In managing autonomic neuropathy symptoms, include specific interventions indicated by the manifestations (for example, for abnormal sweating or nocturnal diarrhoea).	
stepwise manner	0	1.2263	1	Be aware that the drugs in dual therapy should be introduced in a stepwise manner, checking for tolerability and effectiveness of each drug.	
sucrose-containing foods	0	1.2263	1	Advise adults with type 2 diabetes that limited substitution of sucrose-containing foods for other carbohydrate in the meal plan is allowable, but that they should take care to avoid excess energy intake.	
sudden loss	0	1.2263	1	Arrange emergency review by an ophthalmologist for: sudden loss of vision rubeosis iridis pre-retinal or vitreous haemorrhage retinal detachment.	
suspected hypoglycaemia	0	1.2263	1	Consider short-term self-monitoring of blood glucose levels in adults with type 2 diabetes (and review treatment as necessary): when starting treatment with oral or intravenous corticosteroids or to confirm suspected hypoglycaemia.	
sympathetic nervous	0	1.2263	1	Think about the possibility of contributory sympathetic nervous system damage for adults with type 2 diabetes who lose the warning signs of hypoglycaemia. 2009, amended 2015	
system damage	0	1.2263	1	Think about the possibility of contributory sympathetic nervous system damage for adults with type 2 diabetes who lose the warning signs of hypoglycaemia. 2009, amended 2015	
treatment options	0	1.2263	1	Assess, educate and support men with type 2 diabetes who have problematic erectile dysfunction, addressing contributory factors such as cardiovascular disease as well as possible treatment options.	
treatment recommendations	0	1.2263	0	
unexplained bladder-emptying	0	1.2263	1	Investigate the possibility of autonomic neuropathy affecting the bladder in adults with type 2 diabetes who have unexplained bladder-emptying problems.	
vessel formation	0	1.2263	1	Arrange rapid review by an ophthalmologist for new vessel formation.	
vision rubeosis	0	1.2263	1	Arrange emergency review by an ophthalmologist for: sudden loss of vision rubeosis iridis pre-retinal or vitreous haemorrhage retinal detachment.	
visual impairment	0	1.2263	1	Take into account any disabilities, including visual impairment, when planning and delivering care for adults with type 2 diabetes.	
vitreous haemorrhage	0	1.2263	1	Arrange emergency review by an ophthalmologist for: sudden loss of vision rubeosis iridis pre-retinal or vitreous haemorrhage retinal detachment.	
structured education	0	1.1952	3	Offer structured education to adults with type 2 diabetes and or their family members or carers (as appropriate) at and around the time of diagnosis, with	Explain to people and their carers that structured education is an integral part of diabetes care.	Ensure that any structured education programme for adults with type 2 diabetes includes the following components:	
oral drugs	0	1.1911	2	If triple therapy with metformin and 2 other oral drugs (see recommendation ) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities.	In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, and if dual therapy with 2 oral drugs (see recommendation ) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider insulin-based treatment (see recommendations – ).	
balanced eating	0	1.1799	1	Emphasise advice on healthy balanced eating that is applicable to the general population when providing advice to adults with type 2 diabetes	
dairy products	0	1.1799	1	Encourage high-fibre, low-glycaemic-index sources of carbohydrate in the diet, such as fruit, vegetables, wholegrains and pulses; include low-fat dairy products and oily fish; and control the intake of foods containing saturated and trans fatty acids.	
diabetes encourage	0	1.1799	0	
emphasise advice	0	1.1799	1	Emphasise advice on healthy balanced eating that is applicable to the general population when providing advice to adults with type 2 diabetes	
encourage high-fibre	0	1.1799	1	Encourage high-fibre, low-glycaemic-index sources of carbohydrate in the diet, such as fruit, vegetables, wholegrains and pulses; include low-fat dairy products and oily fish; and control the intake of foods containing saturated and trans fatty acids.	
fatty acids	0	1.1799	1	Encourage high-fibre, low-glycaemic-index sources of carbohydrate in the diet, such as fruit, vegetables, wholegrains and pulses; include low-fat dairy products and oily fish; and control the intake of foods containing saturated and trans fatty acids.	
general population	1	1.1799	1	Emphasise advice on healthy balanced eating that is applicable to the general population when providing advice to adults with type 2 diabetes	
healthy balanced	0	1.1799	1	Emphasise advice on healthy balanced eating that is applicable to the general population when providing advice to adults with type 2 diabetes	
low-fat dairy	0	1.1799	1	Encourage high-fibre, low-glycaemic-index sources of carbohydrate in the diet, such as fruit, vegetables, wholegrains and pulses; include low-fat dairy products and oily fish; and control the intake of foods containing saturated and trans fatty acids.	
low-glycaemic-index sources	0	1.1799	1	Encourage high-fibre, low-glycaemic-index sources of carbohydrate in the diet, such as fruit, vegetables, wholegrains and pulses; include low-fat dairy products and oily fish; and control the intake of foods containing saturated and trans fatty acids.	
oily fish	0	1.1799	1	Encourage high-fibre, low-glycaemic-index sources of carbohydrate in the diet, such as fruit, vegetables, wholegrains and pulses; include low-fat dairy products and oily fish; and control the intake of foods containing saturated and trans fatty acids.	
trans fatty	0	1.1799	1	Encourage high-fibre, low-glycaemic-index sources of carbohydrate in the diet, such as fruit, vegetables, wholegrains and pulses; include low-fat dairy products and oily fish; and control the intake of foods containing saturated and trans fatty acids.	
oral medication	0	1.1332	1	Do not routinely offer self-monitoring of blood glucose levels for adults with type 2 diabetes unless: the person is on insulin or there is evidence of hypoglycaemic episodes or the person is on oral medication that may increase their risk of hypoglycaemia while driving or operating machinery or	
adverse effects	0	1.1301	6	When prescribing pioglitazone, exercise particular caution if the person is at high risk of the adverse effects of the drug	When prescribing pioglitazone, exercise particular caution if the person is at high risk of the adverse effects of the drug	When prescribing pioglitazone, exercise particular caution if the person is at high risk of the adverse effects of the drug	When prescribing pioglitazone, exercise particular caution if the person is at high risk of the adverse effects of the drug	Check for possible adverse effects of antihypertensive drug treatment – including the risks from unnecessarily low blood pressure.	Encourage them to achieve the target and maintain it unless any resulting adverse effects (including hypoglycaemia), or their efforts to achieve their target, impair their quality of life.	
initial drug	0	1.1236	6	Initial drug treatment	Initial drug treatment	Offer standard-release metformin as the initial drug treatment for adults with type 2 diabetes.	In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, consider initial drug treatment with: a dipeptidyl peptidase-4 (DPP-4) inhibitor or pioglitazone or a sulfonylurea.	In adults with type 2 diabetes, if initial drug treatment with metformin has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider dual therapy with: metformin and a DPP-4 inhibitor or metformin and pioglitazone or metformin and a sulfonylurea.	In adults with type 2 diabetes, if metformin is contraindicated or not tolerated and initial drug treatment has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider dual therapy with: a DPP-4 inhibitor and pioglitazone or a DPP-4 inhibitor and a sulfonylurea or pioglitazone and a sulfonylurea.	
antihypertensive drug	0	1.1235	7	For an adult with type 2 diabetes on antihypertensive drug treatment when diabetes is diagnosed, review blood pressure control and medications used.	Monitor blood pressure every 1–2 months, and intensify therapy if the person is already on antihypertensive drug treatment, until the blood pressure is consistently below 140 80 mmHg (below 130 80 mmHg if there is kidney, eye or cerebrovascular damage).	First-line antihypertensive drug treatment should be a once-daily, generic angiotensin-converting enzyme (ACE) inhibitor	The first-line antihypertensive drug treatment for a person of African or	A calcium-channel blocker should be the first-line antihypertensive drug treatment for a woman for whom, after an informed discussion, it is agreed there is a possibility of her becoming pregnant.	Check for possible adverse effects of antihypertensive drug treatment – including the risks from unnecessarily low blood pressure.	When using tricyclic drugs and antihypertensive drug treatments in adults with type 2 diabetes who have autonomic neuropathy, be aware of the increased likelihood of side effects such as orthostatic hypotension.	
glucagon-like peptide-1	1	1.1186	2	Recommendations in this section that cover dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) mimetics and sulfonylureas refer to each of these groups of drugs at a class level.	If triple therapy with metformin and 2 other oral drugs (see recommendation ) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities.	
weight loss	0	1.1146	7	Remember that lesser degrees of weight loss may still be of benefit, and that larger degrees of weight loss in the longer term will have advantageous metabolic impact.	HbA1c and a weight loss of at least 3percent of initial body weight in 6 months).	Remember that lesser degrees of weight loss may still be of benefit, and that larger degrees of weight loss in the longer term will have advantageous metabolic impact.	HbA1c and a weight loss of at least 3percent of initial body weight in 6 months).	For adults with type 2 diabetes who are overweight, set an initial body weight loss target of 5–10percent	Be aware that there are other possible reasons for a low HbA1c level, for example, deteriorating renal function or sudden weight loss.	If triple therapy with metformin and 2 other oral drugs (see recommendation ) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities.	
healthcare products	0	1.0919	10	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2017) warned that canagliflozin may increase the risk of lower-limb amputation (mainly toes) in people with type 2 diabetes	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) notes that cases of cardiac failure have been reported when pioglitazone was used in combination with insulin, especially in patients with risk factors for the development of cardiac failure	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2014) notes that domperidone is associated with a small increased risk of serious cardiac side effects	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2017) warned that canagliflozin may increase the risk of lower-limb amputation (mainly toes) in people with type 2 diabetes	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) notes that cases of cardiac failure have been reported when pioglitazone was used in combination with insulin, especially in patients with risk factors for the development of cardiac failure	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2014) notes that domperidone is associated with a small increased risk of serious cardiac side effects	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) advises that 'prescribers should review the safety and efficacy of pioglitazone in individuals after 3–6 months of treatment to ensure that only patients who are deriving benefit continue to be treated'.	Last updated May 2017 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost).	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) advises that 'prescribers should review the safety and efficacy of pioglitazone in individuals after 3–6 months of treatment to ensure that only patients who are deriving benefit continue to be treated'.	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2016) warned that serious, life-threatening, and fatal cases of diabetic ketoacidosis have been reported rarely in people taking an SGLT-2 inhibitor (a substantial proportion of the cases concerned off-label use in people with type 1 diabetes, which is not recommended)	
products regulatory	0	1.0919	10	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2017) warned that canagliflozin may increase the risk of lower-limb amputation (mainly toes) in people with type 2 diabetes	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) notes that cases of cardiac failure have been reported when pioglitazone was used in combination with insulin, especially in patients with risk factors for the development of cardiac failure	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2014) notes that domperidone is associated with a small increased risk of serious cardiac side effects	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2017) warned that canagliflozin may increase the risk of lower-limb amputation (mainly toes) in people with type 2 diabetes	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) notes that cases of cardiac failure have been reported when pioglitazone was used in combination with insulin, especially in patients with risk factors for the development of cardiac failure	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2014) notes that domperidone is associated with a small increased risk of serious cardiac side effects	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) advises that 'prescribers should review the safety and efficacy of pioglitazone in individuals after 3–6 months of treatment to ensure that only patients who are deriving benefit continue to be treated'.	Last updated May 2017 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost).	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) advises that 'prescribers should review the safety and efficacy of pioglitazone in individuals after 3–6 months of treatment to ensure that only patients who are deriving benefit continue to be treated'.	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2016) warned that serious, life-threatening, and fatal cases of diabetic ketoacidosis have been reported rarely in people taking an SGLT-2 inhibitor (a substantial proportion of the cases concerned off-label use in people with type 1 diabetes, which is not recommended)	
regulatory agency	0	1.0919	10	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2017) warned that canagliflozin may increase the risk of lower-limb amputation (mainly toes) in people with type 2 diabetes	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) notes that cases of cardiac failure have been reported when pioglitazone was used in combination with insulin, especially in patients with risk factors for the development of cardiac failure	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2014) notes that domperidone is associated with a small increased risk of serious cardiac side effects	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2017) warned that canagliflozin may increase the risk of lower-limb amputation (mainly toes) in people with type 2 diabetes	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) notes that cases of cardiac failure have been reported when pioglitazone was used in combination with insulin, especially in patients with risk factors for the development of cardiac failure	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2014) notes that domperidone is associated with a small increased risk of serious cardiac side effects	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) advises that 'prescribers should review the safety and efficacy of pioglitazone in individuals after 3–6 months of treatment to ensure that only patients who are deriving benefit continue to be treated'.	Last updated May 2017 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost).	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) advises that 'prescribers should review the safety and efficacy of pioglitazone in individuals after 3–6 months of treatment to ensure that only patients who are deriving benefit continue to be treated'.	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2016) warned that serious, life-threatening, and fatal cases of diabetic ketoacidosis have been reported rarely in people taking an SGLT-2 inhibitor (a substantial proportion of the cases concerned off-label use in people with type 1 diabetes, which is not recommended)	
acquisition cost	0	1.0877	2	Last updated May 2017 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost).	Consider a phosphodiesterase-5 inhibitor to treat problematic erectile dysfunction in men with type 2 diabetes, initially choosing the drug with the lowest acquisition cost and taking into account any contraindications.	
hba1c level	0	1.0859	7	In adults with type 2 diabetes, measure HbA1c levels at: 3–6-monthly intervals (tailored to individual needs), until the HbA1c is stable on unchanging therapy 6-monthly intervals once the HbA1c level and blood glucose lowering therapy are stable.	For adults with type 2 diabetes managed either by lifestyle and diet, or by lifestyle and diet combined with a single drug not associated with hypoglycaemia, support the person to aim for an HbA1c level of 48 mmol mol ( percent)	For adults on a drug associated with hypoglycaemia, support the person to aim for an HbA1c level of 53 mmol mol ( percent).	In adults with type 2 diabetes, if HbA1c levels are not adequately controlled by a single drug and rise to 58 mmol mol ( percent) or higher: reinforce advice about diet, lifestyle and adherence to drug treatment and support the person to aim for an HbA1c level of 53 mmol mol ( percent) and intensify drug treatment.	Consider relaxing the target HbA1c level (see recommendations and )	If adults with type 2 diabetes achieve an HbA1c level that is lower than their target and they are not experiencing hypoglycaemia, encourage them to maintain it	Be aware that there are other possible reasons for a low HbA1c level, for example, deteriorating renal function or sudden weight loss.	
family members	0	1.0745	3	Offer structured education to adults with type 2 diabetes and or their family members or carers (as appropriate) at and around the time of diagnosis, with	It has specific aims and learning objectives, and supports the person and their family members and carers in developing attitudes, beliefs, knowledge and skills to self-manage diabetes.	Ensure that all members of the diabetes healthcare team are familiar with the patient-education programmes available locally, that these programmes are integrated with the rest of the care pathway, and that adults with type 2 diabetes and their family members or carers (as appropriate) have the opportunity to contribute to the design and provision of local programmes.	
low hba1c	0	1.0514	1	Be aware that there are other possible reasons for a low HbA1c level, for example, deteriorating renal function or sudden weight loss.	
offer standard-release	0	1.0514	1	Offer standard-release metformin as the initial drug treatment for adults with type 2 diabetes.	
renal function	0	1.0514	1	Be aware that there are other possible reasons for a low HbA1c level, for example, deteriorating renal function or sudden weight loss.	
sudden weight	0	1.0514	1	Be aware that there are other possible reasons for a low HbA1c level, for example, deteriorating renal function or sudden weight loss.	
treatment offer	0	1.0514	0	
weight gain	0	1.0342	2	For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services.	It advises that if the combination is used, people should be observed for signs and symptoms of heart failure, weight gain, and oedema	
oral drug	0	1.0144	3	In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation ) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations – ).	If triple therapy with metformin and 2 other oral drugs (see recommendation ) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities.	In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, and if dual therapy with 2 oral drugs (see recommendation ) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider insulin-based treatment (see recommendations – ).	
drug treatments	0	1.0004	1	When using tricyclic drugs and antihypertensive drug treatments in adults with type 2 diabetes who have autonomic neuropathy, be aware of the increased likelihood of side effects such as orthostatic hypotension.	
orthostatic hypotension	0	1.0004	1	When using tricyclic drugs and antihypertensive drug treatments in adults with type 2 diabetes who have autonomic neuropathy, be aware of the increased likelihood of side effects such as orthostatic hypotension.	
tricyclic drugs	0	1.0004	1	When using tricyclic drugs and antihypertensive drug treatments in adults with type 2 diabetes who have autonomic neuropathy, be aware of the increased likelihood of side effects such as orthostatic hypotension.	
unexplained diarrhoea	0	1.0004	1	Think about the possibility of autonomic neuropathy affecting the gut in adults with type 2 diabetes who have unexplained diarrhoea that happens particularly at night 2009, amended 2015	
myocardial infarction	1	0.9889	1	For guidance on the primary and secondary prevention of cardiovascular disease in adults with type 2 diabetes, see the NICE guidelines on cardiovascular disease and myocardial infarction.	
secondary prevention	0	0.9889	1	For guidance on the primary and secondary prevention of cardiovascular disease in adults with type 2 diabetes, see the NICE guidelines on cardiovascular disease and myocardial infarction.	
dual therapy	0	0.9753	8	Add the other drug (that is, the calcium-channel blocker or diuretic) if the target is not reached with dual therapy 2009, amended 2015	Add the other drug (that is, the calcium-channel blocker or diuretic) if the target is not reached with dual therapy 2009, amended 2015	Treatment with 2 non-insulin blood glucose lowering therapies in combination (dual therapy)	In adults with type 2 diabetes, if initial drug treatment with metformin has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider dual therapy with: metformin and a DPP-4 inhibitor or metformin and pioglitazone or metformin and a sulfonylurea.	In adults with type 2 diabetes, if metformin is contraindicated or not tolerated and initial drug treatment has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider dual therapy with: a DPP-4 inhibitor and pioglitazone or a DPP-4 inhibitor and a sulfonylurea or pioglitazone and a sulfonylurea.	In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation ) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations – ).	In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, and if dual therapy with 2 oral drugs (see recommendation ) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider insulin-based treatment (see recommendations – ).	Be aware that the drugs in dual therapy should be introduced in a stepwise manner, checking for tolerability and effectiveness of each drug.	
lifestyle advice	0	0.9675	7	Add medications if lifestyle advice does not reduce blood pressure to below 140 80 mmHg (below 130 80 mmHg if there is kidney, eye or cerebrovascular damage).	Add medications if lifestyle advice does not reduce blood pressure to below 140 80 mmHg (below 130 80 mmHg if there is kidney, eye or cerebrovascular damage).	For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services.	Offer and reinforce preventive lifestyle advice.	Provide lifestyle advice (diet and exercise) at the same time.	Provide lifestyle advice (see section in this guideline and the lifestyle interventions section in hypertension in adults NICE guideline CG127) if blood	Offer lifestyle advice and drug treatment to support adults with type 2 diabetes to achieve and maintain their HbA1c target (see section )	
current medical	0	0.9509	3	DVLA guidance (At a glance guide to the current medical standards of fitness to drive) management of hypoglycaemia management of acute changes in plasma glucose control support from an appropriately trained and experienced healthcare professional.	DVLA guidance (At a glance guide to the current medical standards of fitness to drive) management of hypoglycaemia management of acute changes in plasma glucose control support from an appropriately trained and experienced healthcare professional.	Take the Driver and Vehicle Licensing Agency (DVLA) At a glance guide to the current medical standards of fitness to drive into account when offering self-monitoring of blood glucose levels for adults with type 2 diabetes.	
glance guide	0	0.9509	3	DVLA guidance (At a glance guide to the current medical standards of fitness to drive) management of hypoglycaemia management of acute changes in plasma glucose control support from an appropriately trained and experienced healthcare professional.	DVLA guidance (At a glance guide to the current medical standards of fitness to drive) management of hypoglycaemia management of acute changes in plasma glucose control support from an appropriately trained and experienced healthcare professional.	Take the Driver and Vehicle Licensing Agency (DVLA) At a glance guide to the current medical standards of fitness to drive into account when offering self-monitoring of blood glucose levels for adults with type 2 diabetes.	
licensing agency	0	0.9509	1	Take the Driver and Vehicle Licensing Agency (DVLA) At a glance guide to the current medical standards of fitness to drive into account when offering self-monitoring of blood glucose levels for adults with type 2 diabetes.	
medical standards	0	0.9509	3	DVLA guidance (At a glance guide to the current medical standards of fitness to drive) management of hypoglycaemia management of acute changes in plasma glucose control support from an appropriately trained and experienced healthcare professional.	DVLA guidance (At a glance guide to the current medical standards of fitness to drive) management of hypoglycaemia management of acute changes in plasma glucose control support from an appropriately trained and experienced healthcare professional.	Take the Driver and Vehicle Licensing Agency (DVLA) At a glance guide to the current medical standards of fitness to drive into account when offering self-monitoring of blood glucose levels for adults with type 2 diabetes.	
vehicle licensing	0	0.9509	1	Take the Driver and Vehicle Licensing Agency (DVLA) At a glance guide to the current medical standards of fitness to drive into account when offering self-monitoring of blood glucose levels for adults with type 2 diabetes.	
alternative diagnoses	0	0.9388	1	Think about a diagnosis of gastroparesis in adults with type 2 diabetes with erratic blood glucose control or unexplained gastric bloating or vomiting, taking into account possible alternative diagnoses 2009, amended 2015	
antiemetic therapy	0	0.9388	1	For adults with type 2 diabetes who have vomiting caused by gastroparesis, explain that: there is not strong evidence that any available antiemetic therapy is effective some people have had benefit with domperidone , erythromycin or metoclopramide . the strongest evidence for effectiveness is for domperidone , but prescribers must	
erratic blood	0	0.9388	1	Think about a diagnosis of gastroparesis in adults with type 2 diabetes with erratic blood glucose control or unexplained gastric bloating or vomiting, taking into account possible alternative diagnoses 2009, amended 2015	
strong evidence	0	0.9388	1	For adults with type 2 diabetes who have vomiting caused by gastroparesis, explain that: there is not strong evidence that any available antiemetic therapy is effective some people have had benefit with domperidone , erythromycin or metoclopramide . the strongest evidence for effectiveness is for domperidone , but prescribers must	
unexplained gastric	0	0.9388	1	Think about a diagnosis of gastroparesis in adults with type 2 diabetes with erratic blood glucose control or unexplained gastric bloating or vomiting, taking into account possible alternative diagnoses 2009, amended 2015	
healthcare professional	0	0.926	7	DVLA guidance (At a glance guide to the current medical standards of fitness to drive) management of hypoglycaemia management of acute changes in plasma glucose control support from an appropriately trained and experienced healthcare professional.	Last updated May 2017 who need help from a carer or healthcare professional to administer insulin injections and for whom switching to one of the long-acting insulin analogues would reduce the number of daily injections.	DVLA guidance (At a glance guide to the current medical standards of fitness to drive) management of hypoglycaemia management of acute changes in plasma glucose control support from an appropriately trained and experienced healthcare professional.	Last updated May 2017 who need help from a carer or healthcare professional to administer insulin injections and for whom switching to one of the long-acting insulin analogues would reduce the number of daily injections.	Provide individualised and ongoing nutritional advice from a healthcare professional with specific expertise and competencies in nutrition.	Consider, as an alternative to NPH insulin, using insulin detemir or insulin glargine if: the person needs assistance from a carer or healthcare professional to inject insulin, and use of insulin detemir or insulin glargine would reduce the frequency of injections from twice to once daily or the person's lifestyle is restricted by recurrent symptomatic hypoglycaemic episodes or the person would otherwise need twice-daily NPH insulin injections in combination with oral glucose-lowering drugs.	The MHRA advised that healthcare professionals should test for raised ketones in people with ketoacidosis symptoms who are receiving an SGLT-2 inhibitor, even if their plasma glucose levels are near-normal.	
annual reinforcement	0	0.9235	1	Last updated May 2017 annual reinforcement and review	
integral part	0	0.9235	1	Explain to people and their carers that structured education is an integral part of diabetes care.	
review explain	0	0.9235	0	
single drug	0	0.9118	2	For adults with type 2 diabetes managed either by lifestyle and diet, or by lifestyle and diet combined with a single drug not associated with hypoglycaemia, support the person to aim for an HbA1c level of 48 mmol mol ( percent)	In adults with type 2 diabetes, if HbA1c levels are not adequately controlled by a single drug and rise to 58 mmol mol ( percent) or higher: reinforce advice about diet, lifestyle and adherence to drug treatment and support the person to aim for an HbA1c level of 53 mmol mol ( percent) and intensify drug treatment.	
patient-education programme	0	0.8995	4	Ensure that the patient-education programmes available meet the cultural, linguistic, cognitive and literacy needs within the local area.	Ensure that the patient-education programmes available meet the cultural, linguistic, cognitive and literacy needs within the local area.	Ensure the patient-education programme provides the necessary resources to support the educators, and that educators are properly trained and given time to develop and maintain their skills.	Ensure that all members of the diabetes healthcare team are familiar with the patient-education programmes available locally, that these programmes are integrated with the rest of the care pathway, and that adults with type 2 diabetes and their family members or carers (as appropriate) have the opportunity to contribute to the design and provision of local programmes.	
insulin therapy	0	0.8843	4	If triple therapy with metformin and 2 other oral drugs (see recommendation ) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities.	When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding	When starting insulin therapy in adults with type 2 diabetes, continue to offer metformin for people without contraindications or intolerance	Start insulin therapy for adults with type 2 diabetes from a choice of a number of insulin types and regimens:	
nice guideline	0	0.88	12	For more information about supporting adherence, see the NICE guideline on medicines adherence.	For more information about supporting adherence, see the NICE guideline on medicines adherence.	For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services.	For recommendations on bariatric surgery for people with recent-onset type 2 diabetes, see the section on bariatric surgery for people with recent-onset type 2 diabetes in the NICE guideline on obesity.	Provide lifestyle advice (see section in this guideline and the lifestyle interventions section in hypertension in adults NICE guideline CG127) if blood	For guidance on the primary and secondary prevention of cardiovascular disease in adults with type 2 diabetes, see the NICE guidelines on cardiovascular disease and myocardial infarction.	For guidance on HbA1c targets for women with type 2 diabetes who are pregnant or planning to become pregnant, see the NICE guideline on diabetes in pregnancy.	For more information, see the NICE guideline on diabetes in pregnancy.	For guidance on insulin delivery for adults with type 2 diabetes, see the insulin delivery section in the NICE guideline on type 1 diabetes.	For guidance on managing painful diabetic peripheral neuropathy in adults with type 2 diabetes, see the NICE guideline on neuropathic pain in adults.	For guidance on preventing and managing foot problems in adults with type 2 diabetes, see the NICE guideline on diabetic foot problems.	NICE guideline on chronic kidney disease in adults.	
glucose levels	0	0.8768	8	In several cases, blood glucose levels were only moderately elevated	In several cases, blood glucose levels were only moderately elevated	Take the Driver and Vehicle Licensing Agency (DVLA) At a glance guide to the current medical standards of fitness to drive into account when offering self-monitoring of blood glucose levels for adults with type 2 diabetes.	Do not routinely offer self-monitoring of blood glucose levels for adults with type 2 diabetes unless: the person is on insulin or there is evidence of hypoglycaemic episodes or the person is on oral medication that may increase their risk of hypoglycaemia while driving or operating machinery or	Consider short-term self-monitoring of blood glucose levels in adults with type 2 diabetes (and review treatment as necessary): when starting treatment with oral or intravenous corticosteroids or to confirm suspected hypoglycaemia.	If adults with type 2 diabetes are self-monitoring their blood glucose levels, carry out a structured assessment at least annually	Consider pre-mixed (biphasic) preparations that include short-acting insulin analogues, rather than pre-mixed (biphasic) preparations that include short-acting human insulin preparations, if: a person prefers injecting insulin immediately before a meal or hypoglycaemia is a problem or blood glucose levels rise markedly after meals.	The MHRA advised that healthcare professionals should test for raised ketones in people with ketoacidosis symptoms who are receiving an SGLT-2 inhibitor, even if their plasma glucose levels are near-normal.	
glucose control	0	0.8767	8	If HbA1c monitoring is invalid because of disturbed erythrocyte turnover or abnormal haemoglobin type, estimate trends in blood glucose control using one	DVLA guidance (At a glance guide to the current medical standards of fitness to drive) management of hypoglycaemia management of acute changes in plasma glucose control support from an appropriately trained and experienced healthcare professional.	If HbA1c monitoring is invalid because of disturbed erythrocyte turnover or abnormal haemoglobin type, estimate trends in blood glucose control using one	DVLA guidance (At a glance guide to the current medical standards of fitness to drive) management of hypoglycaemia management of acute changes in plasma glucose control support from an appropriately trained and experienced healthcare professional.	Last updated May 2017 on a case-by-case basis, with particular consideration for people who are older or frail, for adults with type 2 diabetes: who are unlikely to achieve longer-term risk-reduction benefits, for example, people with a reduced life expectancy for whom tight blood glucose control poses a high risk of the consequences of hypoglycaemia, for example, people who are at risk of falling, people who have impaired awareness of hypoglycaemia, and people who drive or operate machinery as part of their job for whom intensive management would not be appropriate, for example, people with significant comorbidities.	If an adult with type 2 diabetes is symptomatically hyperglycaemic, consider insulin (see recommendations – ) or a sulfonylurea, and review treatment when blood glucose control has been achieved.	Monitor adults with type 2 diabetes who are on pre-mixed (biphasic) insulin for the need for a further injection of short-acting insulin before meals or for a change to a basal bolus regimen with NPH insulin or insulin detemir or insulin glargine , if blood glucose control remains inadequate.	Think about a diagnosis of gastroparesis in adults with type 2 diabetes with erratic blood glucose control or unexplained gastric bloating or vomiting, taking into account possible alternative diagnoses 2009, amended 2015	
hba1c levels	0	0.8761	2	In adults with type 2 diabetes, measure HbA1c levels at: 3–6-monthly intervals (tailored to individual needs), until the HbA1c is stable on unchanging therapy 6-monthly intervals once the HbA1c level and blood glucose lowering therapy are stable.	In adults with type 2 diabetes, if HbA1c levels are not adequately controlled by a single drug and rise to 58 mmol mol ( percent) or higher: reinforce advice about diet, lifestyle and adherence to drug treatment and support the person to aim for an HbA1c level of 53 mmol mol ( percent) and intensify drug treatment.	
hba1c target	0	0.869	3	Involve adults with type 2 diabetes in decisions about their individual HbA1c target	Offer lifestyle advice and drug treatment to support adults with type 2 diabetes to achieve and maintain their HbA1c target (see section )	For guidance on HbA1c targets for women with type 2 diabetes who are pregnant or planning to become pregnant, see the NICE guideline on diabetes in pregnancy.	
chronic kidney	0	0.8628	1	NICE guideline on chronic kidney disease in adults.	
diabetic foot	0	0.8628	3	Diabetic foot problems	Diabetic foot problems	For guidance on preventing and managing foot problems in adults with type 2 diabetes, see the NICE guideline on diabetic foot problems.	
1–2 months	0	0.8612	1	Monitor blood pressure every 1–2 months, and intensify therapy if the person is already on antihypertensive drug treatment, until the blood pressure is consistently below 140 80 mmHg (below 130 80 mmHg if there is kidney, eye or cerebrovascular damage).	
adults nice	0	0.8612	1	Provide lifestyle advice (see section in this guideline and the lifestyle interventions section in hypertension in adults NICE guideline CG127) if blood	
blood type	0	0.8612	0	
guideline cg127	0	0.8612	1	Provide lifestyle advice (see section in this guideline and the lifestyle interventions section in hypertension in adults NICE guideline CG127) if blood	
interventions section	0	0.8612	1	Provide lifestyle advice (see section in this guideline and the lifestyle interventions section in hypertension in adults NICE guideline CG127) if blood	
lifestyle interventions	0	0.8612	1	Provide lifestyle advice (see section in this guideline and the lifestyle interventions section in hypertension in adults NICE guideline CG127) if blood	
monitor blood	0	0.8612	1	Monitor blood pressure every 1–2 months, and intensify therapy if the person is already on antihypertensive drug treatment, until the blood pressure is consistently below 140 80 mmHg (below 130 80 mmHg if there is kidney, eye or cerebrovascular damage).	
failure type	0	0.858	0	
offer lifestyle	0	0.8568	1	Offer lifestyle advice and drug treatment to support adults with type 2 diabetes to achieve and maintain their HbA1c target (see section )	
nice guidelines	0	0.8525	2	For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services.	For guidance on the primary and secondary prevention of cardiovascular disease in adults with type 2 diabetes, see the NICE guidelines on cardiovascular disease and myocardial infarction.	
insulin glargine	0	0.8489	5	Consider, as an alternative to NPH insulin, using insulin detemir or insulin glargine if: the person needs assistance from a carer or healthcare professional to inject insulin, and use of insulin detemir or insulin glargine would reduce the frequency of injections from twice to once daily or the person's lifestyle is restricted by recurrent symptomatic hypoglycaemic episodes or the person would otherwise need twice-daily NPH insulin injections in combination with oral glucose-lowering drugs.	Consider switching to insulin detemir or insulin glargine from NPH insulin in adults with type 2 diabetes: who do not reach their target HbA1c because of significant hypoglycaemia or who experience significant hypoglycaemia on NPH insulin irrespective of the level of	Monitor adults with type 2 diabetes who are on a basal insulin regimen (NPH insulin, insulin detemir or insulin glargine ) for the need for short-acting insulin before meals (or a pre-mixed biphasic insulin preparation).	Monitor adults with type 2 diabetes who are on pre-mixed (biphasic) insulin for the need for a further injection of short-acting insulin before meals or for a change to a basal bolus regimen with NPH insulin or insulin detemir or insulin glargine , if blood glucose control remains inadequate.	The recommendations in this guideline also apply to any current and future biosimilar product(s) of insulin glargine that have an appropriate marketing authorisation that allows the use of the biosimilar(s) in the same indication.	
type 1	1	0.8485	2	For guidance on insulin delivery for adults with type 2 diabetes, see the insulin delivery section in the NICE guideline on type 1 diabetes.	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2016) warned that serious, life-threatening, and fatal cases of diabetic ketoacidosis have been reported rarely in people taking an SGLT-2 inhibitor (a substantial proportion of the cases concerned off-label use in people with type 1 diabetes, which is not recommended)	
drug treatment	0	0.848	24	Initial drug treatment	First intensification of drug treatment	Second intensification of drug treatment	For an adult with type 2 diabetes on antihypertensive drug treatment when diabetes is diagnosed, review blood pressure control and medications used.	Make changes only if there is poor control or if current drug treatment is not appropriate because of microvascular complications or metabolic problems.	Monitor blood pressure every 1–2 months, and intensify therapy if the person is already on antihypertensive drug treatment, until the blood pressure is consistently below 140 80 mmHg (below 130 80 mmHg if there is kidney, eye or cerebrovascular damage).	First-line antihypertensive drug treatment should be a once-daily, generic angiotensin-converting enzyme (ACE) inhibitor	The first-line antihypertensive drug treatment for a person of African or	A calcium-channel blocker should be the first-line antihypertensive drug treatment for a woman for whom, after an informed discussion, it is agreed there is a possibility of her becoming pregnant.	Check for possible adverse effects of antihypertensive drug treatment – including the risks from unnecessarily low blood pressure.	Offer lifestyle advice and drug treatment to support adults with type 2 diabetes to achieve and maintain their HbA1c target (see section )	In adults with type 2 diabetes, if HbA1c levels are not adequately controlled by a single drug and rise to 58 mmol mol ( percent) or higher: reinforce advice about diet, lifestyle and adherence to drug treatment and support the person to aim for an HbA1c level of 53 mmol mol ( percent) and intensify drug treatment.	Drug treatment	For adults with type 2 diabetes, discuss the benefits and risks of drug treatment, and the options available	Base the choice of drug treatment(s) on: the effectiveness of the drug treatment(s) in terms of metabolic response	Last updated May 2017 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost).	Initial drug treatment	Offer standard-release metformin as the initial drug treatment for adults with type 2 diabetes.	In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, consider initial drug treatment with: a dipeptidyl peptidase-4 (DPP-4) inhibitor or pioglitazone or a sulfonylurea.	First intensification of drug treatment	In adults with type 2 diabetes, if initial drug treatment with metformin has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider dual therapy with: metformin and a DPP-4 inhibitor or metformin and pioglitazone or metformin and a sulfonylurea.	In adults with type 2 diabetes, if metformin is contraindicated or not tolerated and initial drug treatment has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider dual therapy with: a DPP-4 inhibitor and pioglitazone or a DPP-4 inhibitor and a sulfonylurea or pioglitazone and a sulfonylurea.	Second intensification of drug treatment	When using tricyclic drugs and antihypertensive drug treatments in adults with type 2 diabetes who have autonomic neuropathy, be aware of the increased likelihood of side effects such as orthostatic hypotension.	
hypoglycaemic episodes	0	0.848	2	Do not routinely offer self-monitoring of blood glucose levels for adults with type 2 diabetes unless: the person is on insulin or there is evidence of hypoglycaemic episodes or the person is on oral medication that may increase their risk of hypoglycaemia while driving or operating machinery or	Consider, as an alternative to NPH insulin, using insulin detemir or insulin glargine if: the person needs assistance from a carer or healthcare professional to inject insulin, and use of insulin detemir or insulin glargine would reduce the frequency of injections from twice to once daily or the person's lifestyle is restricted by recurrent symptomatic hypoglycaemic episodes or the person would otherwise need twice-daily NPH insulin injections in combination with oral glucose-lowering drugs.	
delivery section	0	0.8414	1	For guidance on insulin delivery for adults with type 2 diabetes, see the insulin delivery section in the NICE guideline on type 1 diabetes.	
sodium–glucose cotransporter	0	0.8363	2	Treatment with sodium–glucose cotransporter 2 (SGLT-2) inhibitors , may be appropriate for some adults with type 2 diabetes if metformin is contraindicated or not tolerated (see NICE's guidance on canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes).	Treatment with combinations of medicines including sodium–glucose cotransporter 2 (SGLT-2) inhibitors , may be appropriate for some people with type 2 diabetes; see the NICE guidance on canagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in combination therapy for treating type 2 diabetes and empagliflozin in combination therapy for treating type 2 diabetes.	
care pathway	0	0.8327	1	Ensure that all members of the diabetes healthcare team are familiar with the patient-education programmes available locally, that these programmes are integrated with the rest of the care pathway, and that adults with type 2 diabetes and their family members or carers (as appropriate) have the opportunity to contribute to the design and provision of local programmes.	
diabetes healthcare	0	0.8327	1	Ensure that all members of the diabetes healthcare team are familiar with the patient-education programmes available locally, that these programmes are integrated with the rest of the care pathway, and that adults with type 2 diabetes and their family members or carers (as appropriate) have the opportunity to contribute to the design and provision of local programmes.	
healthcare team	0	0.8327	1	Ensure that all members of the diabetes healthcare team are familiar with the patient-education programmes available locally, that these programmes are integrated with the rest of the care pathway, and that adults with type 2 diabetes and their family members or carers (as appropriate) have the opportunity to contribute to the design and provision of local programmes.	
local programmes	0	0.8327	1	Ensure that all members of the diabetes healthcare team are familiar with the patient-education programmes available locally, that these programmes are integrated with the rest of the care pathway, and that adults with type 2 diabetes and their family members or carers (as appropriate) have the opportunity to contribute to the design and provision of local programmes.	
glucose measurements	0	0.8081	1	Investigate unexplained discrepancies between HbA1c and other glucose measurements	
individual hba1c	0	0.8081	1	Involve adults with type 2 diabetes in decisions about their individual HbA1c target	
investigate unexplained	0	0.8081	1	Investigate unexplained discrepancies between HbA1c and other glucose measurements	
involve adults	0	0.8081	1	Involve adults with type 2 diabetes in decisions about their individual HbA1c target	
measurements involve	0	0.8081	0	
target encourage	0	0.8081	0	
unexplained discrepancies	0	0.8081	1	Investigate unexplained discrepancies between HbA1c and other glucose measurements	
nph insulin	1	0.7997	8	Offer NPH insulin injected once or twice daily according to need.	HbA1c reached or who cannot use the device needed to inject NPH insulin but who could administer their own insulin safely and accurately if a switch to one of the long-acting insulin analogues was made or	Offer NPH insulin injected once or twice daily according to need.	HbA1c reached or who cannot use the device needed to inject NPH insulin but who could administer their own insulin safely and accurately if a switch to one of the long-acting insulin analogues was made or	Consider, as an alternative to NPH insulin, using insulin detemir or insulin glargine if: the person needs assistance from a carer or healthcare professional to inject insulin, and use of insulin detemir or insulin glargine would reduce the frequency of injections from twice to once daily or the person's lifestyle is restricted by recurrent symptomatic hypoglycaemic episodes or the person would otherwise need twice-daily NPH insulin injections in combination with oral glucose-lowering drugs.	Consider switching to insulin detemir or insulin glargine from NPH insulin in adults with type 2 diabetes: who do not reach their target HbA1c because of significant hypoglycaemia or who experience significant hypoglycaemia on NPH insulin irrespective of the level of	Monitor adults with type 2 diabetes who are on a basal insulin regimen (NPH insulin, insulin detemir or insulin glargine ) for the need for short-acting insulin before meals (or a pre-mixed biphasic insulin preparation).	Monitor adults with type 2 diabetes who are on pre-mixed (biphasic) insulin for the need for a further injection of short-acting insulin before meals or for a change to a basal bolus regimen with NPH insulin or insulin detemir or insulin glargine , if blood glucose control remains inadequate.	
local eye	0	0.7975	1	On diagnosis, GPs should immediately refer adults with type 2 diabetes to the local eye screening service	
screening service	0	0.7975	1	On diagnosis, GPs should immediately refer adults with type 2 diabetes to the local eye screening service	
screening systems	0	0.7975	1	Explain the reasons for, and success of, eye screening systems to adults with type 2 diabetes, so that attendance is not reduced by lack of knowledge or fear of outcome.	
service type	0	0.7975	0	
3–6-monthly intervals	0	0.7974	1	In adults with type 2 diabetes, measure HbA1c levels at: 3–6-monthly intervals (tailored to individual needs), until the HbA1c is stable on unchanging therapy 6-monthly intervals once the HbA1c level and blood glucose lowering therapy are stable.	
6-monthly intervals	0	0.7974	1	In adults with type 2 diabetes, measure HbA1c levels at: 3–6-monthly intervals (tailored to individual needs), until the HbA1c is stable on unchanging therapy 6-monthly intervals once the HbA1c level and blood glucose lowering therapy are stable.	
hba1c measurement	0	0.7974	1	HbA1c measurement and targets	
measure hba1c	0	0.7974	2	In adults with type 2 diabetes, measure HbA1c levels at: 3–6-monthly intervals (tailored to individual needs), until the HbA1c is stable on unchanging therapy 6-monthly intervals once the HbA1c level and blood glucose lowering therapy are stable.	Use methods to measure HbA1c that have been calibrated according to	
therapy 6-monthly	0	0.7974	1	In adults with type 2 diabetes, measure HbA1c levels at: 3–6-monthly intervals (tailored to individual needs), until the HbA1c is stable on unchanging therapy 6-monthly intervals once the HbA1c level and blood glucose lowering therapy are stable.	
unchanging therapy	0	0.7974	1	In adults with type 2 diabetes, measure HbA1c levels at: 3–6-monthly intervals (tailored to individual needs), until the HbA1c is stable on unchanging therapy 6-monthly intervals once the HbA1c level and blood glucose lowering therapy are stable.	
cerebrovascular damage	0	0.7964	6	Last updated May 2017 pressure is confirmed as being consistently above 140 80 mmHg (or above 130 80 mmHg if there is kidney, eye or cerebrovascular damage).	Add medications if lifestyle advice does not reduce blood pressure to below 140 80 mmHg (below 130 80 mmHg if there is kidney, eye or cerebrovascular damage).	Last updated May 2017 pressure is confirmed as being consistently above 140 80 mmHg (or above 130 80 mmHg if there is kidney, eye or cerebrovascular damage).	Add medications if lifestyle advice does not reduce blood pressure to below 140 80 mmHg (below 130 80 mmHg if there is kidney, eye or cerebrovascular damage).	Repeat blood pressure measurements within: 1 month if blood pressure is higher than 150 90 mmHg 2 months if blood pressure is higher than 140 80 mmHg 2 months if blood pressure is higher than 130 80 mmHg and there is kidney, eye or cerebrovascular damage.	Monitor blood pressure every 1–2 months, and intensify therapy if the person is already on antihypertensive drug treatment, until the blood pressure is consistently below 140 80 mmHg (below 130 80 mmHg if there is kidney, eye or cerebrovascular damage).	
continued benefit	0	0.7937	1	The assessment should include: the person's self-monitoring skills the quality and frequency of testing checking that the person knows how to interpret the blood glucose results and what action to take the impact on the person's quality of life the continued benefit to the person the equipment used.	
glucose results	0	0.7937	1	The assessment should include: the person's self-monitoring skills the quality and frequency of testing checking that the person knows how to interpret the blood glucose results and what action to take the impact on the person's quality of life the continued benefit to the person the equipment used.	
self-monitoring skills	0	0.7937	1	The assessment should include: the person's self-monitoring skills the quality and frequency of testing checking that the person knows how to interpret the blood glucose results and what action to take the impact on the person's quality of life the continued benefit to the person the equipment used.	
structured assessment	0	0.7937	1	If adults with type 2 diabetes are self-monitoring their blood glucose levels, carry out a structured assessment at least annually	
cases concerned	0	0.7896	1	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2016) warned that serious, life-threatening, and fatal cases of diabetic ketoacidosis have been reported rarely in people taking an SGLT-2 inhibitor (a substantial proportion of the cases concerned off-label use in people with type 1 diabetes, which is not recommended)	
concerned off-label	0	0.7896	1	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2016) warned that serious, life-threatening, and fatal cases of diabetic ketoacidosis have been reported rarely in people taking an SGLT-2 inhibitor (a substantial proportion of the cases concerned off-label use in people with type 1 diabetes, which is not recommended)	
diabetes type	0	0.7896	0	
diabetic ketoacidosis	0	0.7896	3	Last updated May 2017 hepatic impairment diabetic ketoacidosis current, or a history of, bladder cancer uninvestigated macroscopic haematuria.	Last updated May 2017 hepatic impairment diabetic ketoacidosis current, or a history of, bladder cancer uninvestigated macroscopic haematuria.	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2016) warned that serious, life-threatening, and fatal cases of diabetic ketoacidosis have been reported rarely in people taking an SGLT-2 inhibitor (a substantial proportion of the cases concerned off-label use in people with type 1 diabetes, which is not recommended)	
estimated glomerular	0	0.7896	1	In adults with type 2 diabetes, review the dose of metformin if the estimated glomerular filtration rate (eGFR) is below 45 ml minute m2:	
fatal cases	0	0.7896	1	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2016) warned that serious, life-threatening, and fatal cases of diabetic ketoacidosis have been reported rarely in people taking an SGLT-2 inhibitor (a substantial proportion of the cases concerned off-label use in people with type 1 diabetes, which is not recommended)	
filtration rate	0	0.7896	1	In adults with type 2 diabetes, review the dose of metformin if the estimated glomerular filtration rate (eGFR) is below 45 ml minute m2:	
glomerular filtration	0	0.7896	1	In adults with type 2 diabetes, review the dose of metformin if the estimated glomerular filtration rate (eGFR) is below 45 ml minute m2:	
healthcare professionals	0	0.7896	1	The MHRA advised that healthcare professionals should test for raised ketones in people with ketoacidosis symptoms who are receiving an SGLT-2 inhibitor, even if their plasma glucose levels are near-normal.	
ketoacidosis symptoms	0	0.7896	1	The MHRA advised that healthcare professionals should test for raised ketones in people with ketoacidosis symptoms who are receiving an SGLT-2 inhibitor, even if their plasma glucose levels are near-normal.	
kidney function	0	0.7896	1	Prescribe metformin with caution for those at risk of a sudden deterioration in kidney function and those at risk of eGFR falling below 45 ml minute m2.	
plasma glucose	0	0.7896	5	Last updated May 2017 of the following: quality-controlled plasma glucose profiles total glycated haemoglobin estimation (if abnormal haemoglobins) fructosamine estimation.	DVLA guidance (At a glance guide to the current medical standards of fitness to drive) management of hypoglycaemia management of acute changes in plasma glucose control support from an appropriately trained and experienced healthcare professional.	Last updated May 2017 of the following: quality-controlled plasma glucose profiles total glycated haemoglobin estimation (if abnormal haemoglobins) fructosamine estimation.	DVLA guidance (At a glance guide to the current medical standards of fitness to drive) management of hypoglycaemia management of acute changes in plasma glucose control support from an appropriately trained and experienced healthcare professional.	The MHRA advised that healthcare professionals should test for raised ketones in people with ketoacidosis symptoms who are receiving an SGLT-2 inhibitor, even if their plasma glucose levels are near-normal.	
prescribe metformin	0	0.7896	1	Prescribe metformin with caution for those at risk of a sudden deterioration in kidney function and those at risk of eGFR falling below 45 ml minute m2.	
substantial proportion	0	0.7896	1	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2016) warned that serious, life-threatening, and fatal cases of diabetic ketoacidosis have been reported rarely in people taking an SGLT-2 inhibitor (a substantial proportion of the cases concerned off-label use in people with type 1 diabetes, which is not recommended)	
sudden deterioration	0	0.7896	1	Prescribe metformin with caution for those at risk of a sudden deterioration in kidney function and those at risk of eGFR falling below 45 ml minute m2.	
ethnic groups	0	0.7867	1	If triple therapy with metformin and 2 other oral drugs (see recommendation ) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities.	
kg m2	0	0.7867	1	If triple therapy with metformin and 2 other oral drugs (see recommendation ) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities.	
kg m2and	0	0.7867	1	If triple therapy with metformin and 2 other oral drugs (see recommendation ) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities.	
medical problems	0	0.7867	1	If triple therapy with metformin and 2 other oral drugs (see recommendation ) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities.	
minority ethnic	0	0.7867	1	If triple therapy with metformin and 2 other oral drugs (see recommendation ) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities.	
obesity-related comorbidities	0	0.7867	1	If triple therapy with metformin and 2 other oral drugs (see recommendation ) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities.	
occupational implications	0	0.7867	1	If triple therapy with metformin and 2 other oral drugs (see recommendation ) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities.	
significant obesity-related	0	0.7867	1	If triple therapy with metformin and 2 other oral drugs (see recommendation ) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities.	
significant occupational	0	0.7867	1	If triple therapy with metformin and 2 other oral drugs (see recommendation ) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities.	
specific psychological	0	0.7867	1	If triple therapy with metformin and 2 other oral drugs (see recommendation ) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities.	
active insulin	0	0.7863	1	When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding	
dietary understanding	0	0.7863	1	When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding	
injection sites	0	0.7863	1	When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding	
injection technique	0	0.7863	1	When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding	
insulin dose	0	0.7863	1	When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding	
insulin-based treatments	0	0.7863	1	Insulin-based treatments	
intolerance review	0	0.7863	0	
levels dietary	0	0.7863	1	When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding	
repeated injections	0	0.7863	1	When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding	
self-monitoring dose	0	0.7863	1	When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding	
structured programme	0	0.7863	1	When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding	
support self-monitoring	0	0.7863	1	When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding	
telephone support	0	0.7863	1	When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding	
diabetes care	0	0.7786	2	Adopt an individualised approach to diabetes care that is tailored to the needs and circumstances of adults with type 2 diabetes, taking into account their personal preferences, comorbidities, risks from polypharmacy, and their ability to benefit from long-term interventions because of reduced life expectancy.	Explain to people and their carers that structured education is an integral part of diabetes care.	
significant hypoglycaemia	0	0.7701	1	Consider switching to insulin detemir or insulin glargine from NPH insulin in adults with type 2 diabetes: who do not reach their target HbA1c because of significant hypoglycaemia or who experience significant hypoglycaemia on NPH insulin irrespective of the level of	
sglt-2 inhibitors	0	0.7689	2	Treatment with combinations of medicines including SGLT-2 inhibitors , may be appropriate for some people with type 2 diabetes; see the NICE guidance on canagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in triple therapy for treating type 2 diabetes and empagliflozin in combination therapy for treating type 2 diabetes.	Treatment with combinations of medicines including SGLT-2 inhibitors , may be appropriate for some people with type 2 diabetes; see the NICE guidance on canagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in combination therapy for treating type 2 diabetes and empagliflozin in combination therapy for treating type 2 diabetes.	
blood glucose	0	0.759	23	Blood glucose management	If HbA1c monitoring is invalid because of disturbed erythrocyte turnover or abnormal haemoglobin type, estimate trends in blood glucose control using one	In several cases, blood glucose levels were only moderately elevated	Blood glucose management	If HbA1c monitoring is invalid because of disturbed erythrocyte turnover or abnormal haemoglobin type, estimate trends in blood glucose control using one	In several cases, blood glucose levels were only moderately elevated	Treatment with a single non-insulin blood glucose lowering therapy (monotherapy)	Treatment with 2 non-insulin blood glucose lowering therapies in combination (dual therapy)	Treatment with either 3 non-insulin blood glucose lowering therapies in combination (triple therapy) or any treatment combination containing insulin	In adults with type 2 diabetes, measure HbA1c levels at: 3–6-monthly intervals (tailored to individual needs), until the HbA1c is stable on unchanging therapy 6-monthly intervals once the HbA1c level and blood glucose lowering therapy are stable.	Last updated May 2017 on a case-by-case basis, with particular consideration for people who are older or frail, for adults with type 2 diabetes: who are unlikely to achieve longer-term risk-reduction benefits, for example, people with a reduced life expectancy for whom tight blood glucose control poses a high risk of the consequences of hypoglycaemia, for example, people who are at risk of falling, people who have impaired awareness of hypoglycaemia, and people who drive or operate machinery as part of their job for whom intensive management would not be appropriate, for example, people with significant comorbidities.	Self-monitoring of blood glucose	Take the Driver and Vehicle Licensing Agency (DVLA) At a glance guide to the current medical standards of fitness to drive into account when offering self-monitoring of blood glucose levels for adults with type 2 diabetes.	Do not routinely offer self-monitoring of blood glucose levels for adults with type 2 diabetes unless: the person is on insulin or there is evidence of hypoglycaemic episodes or the person is on oral medication that may increase their risk of hypoglycaemia while driving or operating machinery or	Consider short-term self-monitoring of blood glucose levels in adults with type 2 diabetes (and review treatment as necessary): when starting treatment with oral or intravenous corticosteroids or to confirm suspected hypoglycaemia.	If adults with type 2 diabetes are self-monitoring their blood glucose levels, carry out a structured assessment at least annually	The assessment should include: the person's self-monitoring skills the quality and frequency of testing checking that the person knows how to interpret the blood glucose results and what action to take the impact on the person's quality of life the continued benefit to the person the equipment used.	If an adult with type 2 diabetes is symptomatically hyperglycaemic, consider insulin (see recommendations – ) or a sulfonylurea, and review treatment when blood glucose control has been achieved.	Algorithm for blood glucose lowering therapy in adults with type 2 diabetes	Review the continued need for other blood glucose lowering therapies .	Consider pre-mixed (biphasic) preparations that include short-acting insulin analogues, rather than pre-mixed (biphasic) preparations that include short-acting human insulin preparations, if: a person prefers injecting insulin immediately before a meal or hypoglycaemia is a problem or blood glucose levels rise markedly after meals.	Monitor adults with type 2 diabetes who are on pre-mixed (biphasic) insulin for the need for a further injection of short-acting insulin before meals or for a change to a basal bolus regimen with NPH insulin or insulin detemir or insulin glargine , if blood glucose control remains inadequate.	Think about a diagnosis of gastroparesis in adults with type 2 diabetes with erratic blood glucose control or unexplained gastric bloating or vomiting, taking into account possible alternative diagnoses 2009, amended 2015	
triple therapy	0	0.7554	6	If the person's blood pressure is not reduced to the individually agreed target with triple therapy, add an alpha-blocker, a beta-blocker or a potassium-sparing diuretic (the last with caution if the person is already taking an ACE inhibitor or an angiotensin II-receptor antagonist).	If the person's blood pressure is not reduced to the individually agreed target with triple therapy, add an alpha-blocker, a beta-blocker or a potassium-sparing diuretic (the last with caution if the person is already taking an ACE inhibitor or an angiotensin II-receptor antagonist).	Treatment with either 3 non-insulin blood glucose lowering therapies in combination (triple therapy) or any treatment combination containing insulin	In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation ) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations – ).	If triple therapy with metformin and 2 other oral drugs (see recommendation ) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities.	Treatment with combinations of medicines including SGLT-2 inhibitors , may be appropriate for some people with type 2 diabetes; see the NICE guidance on canagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in triple therapy for treating type 2 diabetes and empagliflozin in combination therapy for treating type 2 diabetes.	
nice guidance	0	0.7425	3	Treatment with combinations of medicines including sodium–glucose cotransporter 2 (SGLT-2) inhibitors , may be appropriate for some people with type 2 diabetes; see the NICE guidance on canagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in combination therapy for treating type 2 diabetes and empagliflozin in combination therapy for treating type 2 diabetes.	Treatment with combinations of medicines including SGLT-2 inhibitors , may be appropriate for some people with type 2 diabetes; see the NICE guidance on canagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in triple therapy for treating type 2 diabetes and empagliflozin in combination therapy for treating type 2 diabetes.	Treatment with combinations of medicines including SGLT-2 inhibitors , may be appropriate for some people with type 2 diabetes; see the NICE guidance on canagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in combination therapy for treating type 2 diabetes and empagliflozin in combination therapy for treating type 2 diabetes.	
licensed non-metformin-based	0	0.7367	2	However, discuss with any person for whom repaglinide is being considered, that there is no licensed non-metformin-based combination containing repaglinide that can be offered at first intensification.	However, discuss with any person for whom repaglinide is being considered, that there is no licensed non-metformin-based combination containing repaglinide that can be offered at first intensification.	
non-metformin-based combination	0	0.7367	2	However, discuss with any person for whom repaglinide is being considered, that there is no licensed non-metformin-based combination containing repaglinide that can be offered at first intensification.	However, discuss with any person for whom repaglinide is being considered, that there is no licensed non-metformin-based combination containing repaglinide that can be offered at first intensification.	
basal bolus	0	0.7081	1	Monitor adults with type 2 diabetes who are on pre-mixed (biphasic) insulin for the need for a further injection of short-acting insulin before meals or for a change to a basal bolus regimen with NPH insulin or insulin detemir or insulin glargine , if blood glucose control remains inadequate.	
bolus regimen	0	0.7081	1	Monitor adults with type 2 diabetes who are on pre-mixed (biphasic) insulin for the need for a further injection of short-acting insulin before meals or for a change to a basal bolus regimen with NPH insulin or insulin detemir or insulin glargine , if blood glucose control remains inadequate.	
insulin detemir	0	0.6902	4	Consider, as an alternative to NPH insulin, using insulin detemir or insulin glargine if: the person needs assistance from a carer or healthcare professional to inject insulin, and use of insulin detemir or insulin glargine would reduce the frequency of injections from twice to once daily or the person's lifestyle is restricted by recurrent symptomatic hypoglycaemic episodes or the person would otherwise need twice-daily NPH insulin injections in combination with oral glucose-lowering drugs.	Consider switching to insulin detemir or insulin glargine from NPH insulin in adults with type 2 diabetes: who do not reach their target HbA1c because of significant hypoglycaemia or who experience significant hypoglycaemia on NPH insulin irrespective of the level of	Monitor adults with type 2 diabetes who are on a basal insulin regimen (NPH insulin, insulin detemir or insulin glargine ) for the need for short-acting insulin before meals (or a pre-mixed biphasic insulin preparation).	Monitor adults with type 2 diabetes who are on pre-mixed (biphasic) insulin for the need for a further injection of short-acting insulin before meals or for a change to a basal bolus regimen with NPH insulin or insulin detemir or insulin glargine , if blood glucose control remains inadequate.	
effective treatment	0	0.6818	1	For treating vomiting caused by gastroparesis in adults with type 2 diabetes: consider alternating use of erythomycin and metoclopramide consider domperidone only in exceptional circumstances (if domperidone is the only effective treatment) and in accordance with MHRA guidance.	
exceptional circumstances	0	0.6818	1	For treating vomiting caused by gastroparesis in adults with type 2 diabetes: consider alternating use of erythomycin and metoclopramide consider domperidone only in exceptional circumstances (if domperidone is the only effective treatment) and in accordance with MHRA guidance.	
pressure measurements	0	0.6766	1	Repeat blood pressure measurements within: 1 month if blood pressure is higher than 150 90 mmHg 2 months if blood pressure is higher than 140 80 mmHg 2 months if blood pressure is higher than 130 80 mmHg and there is kidney, eye or cerebrovascular damage.	
repeat blood	0	0.6766	1	Repeat blood pressure measurements within: 1 month if blood pressure is higher than 150 90 mmHg 2 months if blood pressure is higher than 140 80 mmHg 2 months if blood pressure is higher than 130 80 mmHg and there is kidney, eye or cerebrovascular damage.	
human insulin	0	0.6403	3	HbA1c is 75 mmol mol  percent or higher), administered either: separately or as a pre-mixed (biphasic) human insulin preparation.	HbA1c is 75 mmol mol  percent or higher), administered either: separately or as a pre-mixed (biphasic) human insulin preparation.	Consider pre-mixed (biphasic) preparations that include short-acting insulin analogues, rather than pre-mixed (biphasic) preparations that include short-acting human insulin preparations, if: a person prefers injecting insulin immediately before a meal or hypoglycaemia is a problem or blood glucose levels rise markedly after meals.	
insulin analogues	0	0.6403	5	HbA1c reached or who cannot use the device needed to inject NPH insulin but who could administer their own insulin safely and accurately if a switch to one of the long-acting insulin analogues was made or	Last updated May 2017 who need help from a carer or healthcare professional to administer insulin injections and for whom switching to one of the long-acting insulin analogues would reduce the number of daily injections.	HbA1c reached or who cannot use the device needed to inject NPH insulin but who could administer their own insulin safely and accurately if a switch to one of the long-acting insulin analogues was made or	Last updated May 2017 who need help from a carer or healthcare professional to administer insulin injections and for whom switching to one of the long-acting insulin analogues would reduce the number of daily injections.	Consider pre-mixed (biphasic) preparations that include short-acting insulin analogues, rather than pre-mixed (biphasic) preparations that include short-acting human insulin preparations, if: a person prefers injecting insulin immediately before a meal or hypoglycaemia is a problem or blood glucose levels rise markedly after meals.	
insulin preparations	0	0.6403	1	Consider pre-mixed (biphasic) preparations that include short-acting insulin analogues, rather than pre-mixed (biphasic) preparations that include short-acting human insulin preparations, if: a person prefers injecting insulin immediately before a meal or hypoglycaemia is a problem or blood glucose levels rise markedly after meals.	
short-acting human	0	0.6403	1	Consider pre-mixed (biphasic) preparations that include short-acting insulin analogues, rather than pre-mixed (biphasic) preparations that include short-acting human insulin preparations, if: a person prefers injecting insulin immediately before a meal or hypoglycaemia is a problem or blood glucose levels rise markedly after meals.	
mhra guidance	0	0.6306	4	MHRA guidance and summaries of product characteristics	MHRA guidance and summaries of product characteristics	Last updated May 2017 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost).	For treating vomiting caused by gastroparesis in adults with type 2 diabetes: consider alternating use of erythomycin and metoclopramide consider domperidone only in exceptional circumstances (if domperidone is the only effective treatment) and in accordance with MHRA guidance.	
excess weight	0	0.6207	1	For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services.	
harm reduction	0	0.6207	1	For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services.	
health services	1	0.6207	1	For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services.	
mental health	1	0.6207	1	For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services.	
physical activity	0	0.6207	3	Integrate dietary advice with a personalised diabetes management plan, including other aspects of lifestyle modification, such as increasing physical activity and losing weight.	Integrate dietary advice with a personalised diabetes management plan, including other aspects of lifestyle modification, such as increasing physical activity and losing weight.	For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services.	
smoking services	0	0.6207	1	For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services.	
weight management	0	0.6207	1	For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services.	
agency mhra	0	0.5747	1	Last updated May 2017 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost).	
clinical circumstances	0	0.5747	1	Last updated May 2017 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost).	
individual clinical	0	0.5747	1	Last updated May 2017 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost).	
individual preferences	0	0.5747	1	Last updated May 2017 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost).	
licensed indications	0	0.5747	1	Last updated May 2017 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost).	
metabolic response	0	0.5747	3	Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol  percent in	Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol  percent in	Base the choice of drug treatment(s) on: the effectiveness of the drug treatment(s) in terms of metabolic response	
response type	0	0.5747	0	
long-term interventions	0	0.5652	1	Adopt an individualised approach to diabetes care that is tailored to the needs and circumstances of adults with type 2 diabetes, taking into account their personal preferences, comorbidities, risks from polypharmacy, and their ability to benefit from long-term interventions because of reduced life expectancy.	
personal preferences	0	0.5652	1	Adopt an individualised approach to diabetes care that is tailored to the needs and circumstances of adults with type 2 diabetes, taking into account their personal preferences, comorbidities, risks from polypharmacy, and their ability to benefit from long-term interventions because of reduced life expectancy.	
single non-insulin	0	0.5652	1	Treatment with a single non-insulin blood glucose lowering therapy (monotherapy)	
treatment combination	0	0.5652	1	Treatment with either 3 non-insulin blood glucose lowering therapies in combination (triple therapy) or any treatment combination containing insulin	
case-by-case basis	0	0.5546	1	Last updated May 2017 on a case-by-case basis, with particular consideration for people who are older or frail, for adults with type 2 diabetes: who are unlikely to achieve longer-term risk-reduction benefits, for example, people with a reduced life expectancy for whom tight blood glucose control poses a high risk of the consequences of hypoglycaemia, for example, people who are at risk of falling, people who have impaired awareness of hypoglycaemia, and people who drive or operate machinery as part of their job for whom intensive management would not be appropriate, for example, people with significant comorbidities.	
high risk	0	0.5546	5	When prescribing pioglitazone, exercise particular caution if the person is at high risk of the adverse effects of the drug	When prescribing pioglitazone, exercise particular caution if the person is at high risk of the adverse effects of the drug	When prescribing pioglitazone, exercise particular caution if the person is at high risk of the adverse effects of the drug	When prescribing pioglitazone, exercise particular caution if the person is at high risk of the adverse effects of the drug	Last updated May 2017 on a case-by-case basis, with particular consideration for people who are older or frail, for adults with type 2 diabetes: who are unlikely to achieve longer-term risk-reduction benefits, for example, people with a reduced life expectancy for whom tight blood glucose control poses a high risk of the consequences of hypoglycaemia, for example, people who are at risk of falling, people who have impaired awareness of hypoglycaemia, and people who drive or operate machinery as part of their job for whom intensive management would not be appropriate, for example, people with significant comorbidities.	
intensive management	0	0.5546	1	Last updated May 2017 on a case-by-case basis, with particular consideration for people who are older or frail, for adults with type 2 diabetes: who are unlikely to achieve longer-term risk-reduction benefits, for example, people with a reduced life expectancy for whom tight blood glucose control poses a high risk of the consequences of hypoglycaemia, for example, people who are at risk of falling, people who have impaired awareness of hypoglycaemia, and people who drive or operate machinery as part of their job for whom intensive management would not be appropriate, for example, people with significant comorbidities.	
risk-reduction benefits	0	0.5546	1	Last updated May 2017 on a case-by-case basis, with particular consideration for people who are older or frail, for adults with type 2 diabetes: who are unlikely to achieve longer-term risk-reduction benefits, for example, people with a reduced life expectancy for whom tight blood glucose control poses a high risk of the consequences of hypoglycaemia, for example, people who are at risk of falling, people who have impaired awareness of hypoglycaemia, and people who drive or operate machinery as part of their job for whom intensive management would not be appropriate, for example, people with significant comorbidities.	
significant comorbidities	0	0.5546	1	Last updated May 2017 on a case-by-case basis, with particular consideration for people who are older or frail, for adults with type 2 diabetes: who are unlikely to achieve longer-term risk-reduction benefits, for example, people with a reduced life expectancy for whom tight blood glucose control poses a high risk of the consequences of hypoglycaemia, for example, people who are at risk of falling, people who have impaired awareness of hypoglycaemia, and people who drive or operate machinery as part of their job for whom intensive management would not be appropriate, for example, people with significant comorbidities.	
tight blood	0	0.5546	1	Last updated May 2017 on a case-by-case basis, with particular consideration for people who are older or frail, for adults with type 2 diabetes: who are unlikely to achieve longer-term risk-reduction benefits, for example, people with a reduced life expectancy for whom tight blood glucose control poses a high risk of the consequences of hypoglycaemia, for example, people who are at risk of falling, people who have impaired awareness of hypoglycaemia, and people who drive or operate machinery as part of their job for whom intensive management would not be appropriate, for example, people with significant comorbidities.	
life expectancy	0	0.5535	2	Adopt an individualised approach to diabetes care that is tailored to the needs and circumstances of adults with type 2 diabetes, taking into account their personal preferences, comorbidities, risks from polypharmacy, and their ability to benefit from long-term interventions because of reduced life expectancy.	Last updated May 2017 on a case-by-case basis, with particular consideration for people who are older or frail, for adults with type 2 diabetes: who are unlikely to achieve longer-term risk-reduction benefits, for example, people with a reduced life expectancy for whom tight blood glucose control poses a high risk of the consequences of hypoglycaemia, for example, people who are at risk of falling, people who have impaired awareness of hypoglycaemia, and people who drive or operate machinery as part of their job for whom intensive management would not be appropriate, for example, people with significant comorbidities.	
monitor adults	0	0.5528	2	Monitor adults with type 2 diabetes who are on a basal insulin regimen (NPH insulin, insulin detemir or insulin glargine ) for the need for short-acting insulin before meals (or a pre-mixed biphasic insulin preparation).	Monitor adults with type 2 diabetes who are on pre-mixed (biphasic) insulin for the need for a further injection of short-acting insulin before meals or for a change to a basal bolus regimen with NPH insulin or insulin detemir or insulin glargine , if blood glucose control remains inadequate.	
conditions notice-of-rights	0	0.5095	22	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	
short-acting insulin	0	0.5066	4	Consider starting both NPH and short-acting insulin (particularly if the person's	Consider pre-mixed (biphasic) preparations that include short-acting insulin analogues, rather than pre-mixed (biphasic) preparations that include short-acting human insulin preparations, if: a person prefers injecting insulin immediately before a meal or hypoglycaemia is a problem or blood glucose levels rise markedly after meals.	Monitor adults with type 2 diabetes who are on a basal insulin regimen (NPH insulin, insulin detemir or insulin glargine ) for the need for short-acting insulin before meals (or a pre-mixed biphasic insulin preparation).	Monitor adults with type 2 diabetes who are on pre-mixed (biphasic) insulin for the need for a further injection of short-acting insulin before meals or for a change to a basal bolus regimen with NPH insulin or insulin detemir or insulin glargine , if blood glucose control remains inadequate.	
target hba1c	0	0.4624	2	Consider relaxing the target HbA1c level (see recommendations and )	Consider switching to insulin detemir or insulin glargine from NPH insulin in adults with type 2 diabetes: who do not reach their target HbA1c because of significant hypoglycaemia or who experience significant hypoglycaemia on NPH insulin irrespective of the level of	
basal insulin	0	0.3915	1	Monitor adults with type 2 diabetes who are on a basal insulin regimen (NPH insulin, insulin detemir or insulin glargine ) for the need for short-acting insulin before meals (or a pre-mixed biphasic insulin preparation).	
biphasic insulin	0	0.3915	1	Monitor adults with type 2 diabetes who are on a basal insulin regimen (NPH insulin, insulin detemir or insulin glargine ) for the need for short-acting insulin before meals (or a pre-mixed biphasic insulin preparation).	
insulin preparation	0	0.3915	4	HbA1c is 75 mmol mol  percent or higher), administered either: separately or as a pre-mixed (biphasic) human insulin preparation.	HbA1c is 75 mmol mol  percent or higher), administered either: separately or as a pre-mixed (biphasic) human insulin preparation.	Consider pre-mixed (biphasic) preparations that include short-acting insulin analogues, rather than pre-mixed (biphasic) preparations that include short-acting human insulin preparations, if: a person prefers injecting insulin immediately before a meal or hypoglycaemia is a problem or blood glucose levels rise markedly after meals.	Monitor adults with type 2 diabetes who are on a basal insulin regimen (NPH insulin, insulin detemir or insulin glargine ) for the need for short-acting insulin before meals (or a pre-mixed biphasic insulin preparation).	
insulin regimen	0	0.3915	1	Monitor adults with type 2 diabetes who are on a basal insulin regimen (NPH insulin, insulin detemir or insulin glargine ) for the need for short-acting insulin before meals (or a pre-mixed biphasic insulin preparation).	
pre-mixed biphasic	0	0.3915	1	Monitor adults with type 2 diabetes who are on a basal insulin regimen (NPH insulin, insulin detemir or insulin glargine ) for the need for short-acting insulin before meals (or a pre-mixed biphasic insulin preparation).	
glucose-lowering drugs	0	0.3803	1	Consider, as an alternative to NPH insulin, using insulin detemir or insulin glargine if: the person needs assistance from a carer or healthcare professional to inject insulin, and use of insulin detemir or insulin glargine would reduce the frequency of injections from twice to once daily or the person's lifestyle is restricted by recurrent symptomatic hypoglycaemic episodes or the person would otherwise need twice-daily NPH insulin injections in combination with oral glucose-lowering drugs.	
insulin injections	0	0.3803	3	Last updated May 2017 who need help from a carer or healthcare professional to administer insulin injections and for whom switching to one of the long-acting insulin analogues would reduce the number of daily injections.	Last updated May 2017 who need help from a carer or healthcare professional to administer insulin injections and for whom switching to one of the long-acting insulin analogues would reduce the number of daily injections.	Consider, as an alternative to NPH insulin, using insulin detemir or insulin glargine if: the person needs assistance from a carer or healthcare professional to inject insulin, and use of insulin detemir or insulin glargine would reduce the frequency of injections from twice to once daily or the person's lifestyle is restricted by recurrent symptomatic hypoglycaemic episodes or the person would otherwise need twice-daily NPH insulin injections in combination with oral glucose-lowering drugs.	
insulin types	0	0.3803	1	Start insulin therapy for adults with type 2 diabetes from a choice of a number of insulin types and regimens:	
oral glucose-lowering	0	0.3803	1	Consider, as an alternative to NPH insulin, using insulin detemir or insulin glargine if: the person needs assistance from a carer or healthcare professional to inject insulin, and use of insulin detemir or insulin glargine would reduce the frequency of injections from twice to once daily or the person's lifestyle is restricted by recurrent symptomatic hypoglycaemic episodes or the person would otherwise need twice-daily NPH insulin injections in combination with oral glucose-lowering drugs.	
recurrent symptomatic	0	0.3803	1	Consider, as an alternative to NPH insulin, using insulin detemir or insulin glargine if: the person needs assistance from a carer or healthcare professional to inject insulin, and use of insulin detemir or insulin glargine would reduce the frequency of injections from twice to once daily or the person's lifestyle is restricted by recurrent symptomatic hypoglycaemic episodes or the person would otherwise need twice-daily NPH insulin injections in combination with oral glucose-lowering drugs.	
start insulin	0	0.3803	1	Start insulin therapy for adults with type 2 diabetes from a choice of a number of insulin types and regimens:	
symptomatic hypoglycaemic	0	0.3803	1	Consider, as an alternative to NPH insulin, using insulin detemir or insulin glargine if: the person needs assistance from a carer or healthcare professional to inject insulin, and use of insulin detemir or insulin glargine would reduce the frequency of injections from twice to once daily or the person's lifestyle is restricted by recurrent symptomatic hypoglycaemic episodes or the person would otherwise need twice-daily NPH insulin injections in combination with oral glucose-lowering drugs.	
twice-daily nph	0	0.3803	1	Consider, as an alternative to NPH insulin, using insulin detemir or insulin glargine if: the person needs assistance from a carer or healthcare professional to inject insulin, and use of insulin detemir or insulin glargine would reduce the frequency of injections from twice to once daily or the person's lifestyle is restricted by recurrent symptomatic hypoglycaemic episodes or the person would otherwise need twice-daily NPH insulin injections in combination with oral glucose-lowering drugs.	
type 2	1	0.1923	97	Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol  percent in	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2017) warned that canagliflozin may increase the risk of lower-limb amputation (mainly toes) in people with type 2 diabetes	Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol  percent in	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2017) warned that canagliflozin may increase the risk of lower-limb amputation (mainly toes) in people with type 2 diabetes	Be aware that, if metformin is contraindicated or not tolerated, repaglinide is both clinically effective and cost effective in adults with type 2 diabetes	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Adopt an individualised approach to diabetes care that is tailored to the needs and circumstances of adults with type 2 diabetes, taking into account their personal preferences, comorbidities, risks from polypharmacy, and their ability to benefit from long-term interventions because of reduced life expectancy.	Take into account any disabilities, including visual impairment, when planning and delivering care for adults with type 2 diabetes.	Offer structured education to adults with type 2 diabetes and or their family members or carers (as appropriate) at and around the time of diagnosis, with	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Ensure that any structured education programme for adults with type 2 diabetes includes the following components:	Ensure that all members of the diabetes healthcare team are familiar with the patient-education programmes available locally, that these programmes are integrated with the rest of the care pathway, and that adults with type 2 diabetes and their family members or carers (as appropriate) have the opportunity to contribute to the design and provision of local programmes.	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Emphasise advice on healthy balanced eating that is applicable to the general population when providing advice to adults with type 2 diabetes	For adults with type 2 diabetes who are overweight, set an initial body weight loss target of 5–10percent	Advise adults with type 2 diabetes that limited substitution of sucrose-containing foods for other carbohydrate in the meal plan is allowable, but that they should take care to avoid excess energy intake.	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks.	For recommendations on bariatric surgery for people with recent-onset type 2 diabetes, see the section on bariatric surgery for people with recent-onset type 2 diabetes in the NICE guideline on obesity.	Measure blood pressure at least annually in an adult with type 2 diabetes without previously diagnosed hypertension or renal disease	For an adult with type 2 diabetes on antihypertensive drug treatment when diabetes is diagnosed, review blood pressure control and medications used.	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Do not offer antiplatelet therapy (aspirin or clopidogrel) for adults with type 2 diabetes without cardiovascular disease.	For guidance on the primary and secondary prevention of cardiovascular disease in adults with type 2 diabetes, see the NICE guidelines on cardiovascular disease and myocardial infarction.	In adults with type 2 diabetes, measure HbA1c levels at: 3–6-monthly intervals (tailored to individual needs), until the HbA1c is stable on unchanging therapy 6-monthly intervals once the HbA1c level and blood glucose lowering therapy are stable.	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Involve adults with type 2 diabetes in decisions about their individual HbA1c target	Offer lifestyle advice and drug treatment to support adults with type 2 diabetes to achieve and maintain their HbA1c target (see section )	For adults with type 2 diabetes managed either by lifestyle and diet, or by lifestyle and diet combined with a single drug not associated with hypoglycaemia, support the person to aim for an HbA1c level of 48 mmol mol ( percent)	In adults with type 2 diabetes, if HbA1c levels are not adequately controlled by a single drug and rise to 58 mmol mol ( percent) or higher: reinforce advice about diet, lifestyle and adherence to drug treatment and support the person to aim for an HbA1c level of 53 mmol mol ( percent) and intensify drug treatment.	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Last updated May 2017 on a case-by-case basis, with particular consideration for people who are older or frail, for adults with type 2 diabetes: who are unlikely to achieve longer-term risk-reduction benefits, for example, people with a reduced life expectancy for whom tight blood glucose control poses a high risk of the consequences of hypoglycaemia, for example, people who are at risk of falling, people who have impaired awareness of hypoglycaemia, and people who drive or operate machinery as part of their job for whom intensive management would not be appropriate, for example, people with significant comorbidities.	If adults with type 2 diabetes achieve an HbA1c level that is lower than their target and they are not experiencing hypoglycaemia, encourage them to maintain it	For guidance on HbA1c targets for women with type 2 diabetes who are pregnant or planning to become pregnant, see the NICE guideline on diabetes in pregnancy.	Take the Driver and Vehicle Licensing Agency (DVLA) At a glance guide to the current medical standards of fitness to drive into account when offering self-monitoring of blood glucose levels for adults with type 2 diabetes.	Do not routinely offer self-monitoring of blood glucose levels for adults with type 2 diabetes unless: the person is on insulin or there is evidence of hypoglycaemic episodes or the person is on oral medication that may increase their risk of hypoglycaemia while driving or operating machinery or	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Consider short-term self-monitoring of blood glucose levels in adults with type 2 diabetes (and review treatment as necessary): when starting treatment with oral or intravenous corticosteroids or to confirm suspected hypoglycaemia.	Be aware that adults with type 2 diabetes who have acute intercurrent illness are at risk of worsening hyperglycaemia	If adults with type 2 diabetes are self-monitoring their blood glucose levels, carry out a structured assessment at least annually	For adults with type 2 diabetes, discuss the benefits and risks of drug treatment, and the options available	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	If an adult with type 2 diabetes is symptomatically hyperglycaemic, consider insulin (see recommendations – ) or a sulfonylurea, and review treatment when blood glucose control has been achieved.	Offer standard-release metformin as the initial drug treatment for adults with type 2 diabetes.	Gradually increase the dose of standard-release metformin over several weeks to minimise the risk of gastrointestinal side effects in adults with type 2 diabetes.	If an adult with type 2 diabetes experiences gastrointestinal side effects with standard-release metformin, consider a trial of modified-release metformin.	Algorithm for blood glucose lowering therapy in adults with type 2 diabetes	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	In adults with type 2 diabetes, review the dose of metformin if the estimated glomerular filtration rate (eGFR) is below 45 ml minute m2:	In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, consider initial drug treatment with: a dipeptidyl peptidase-4 (DPP-4) inhibitor or pioglitazone or a sulfonylurea.	In adults with type 2 diabetes, do not offer or continue pioglitazone if they have any of the following: heart failure or history of heart failure	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Treatment with sodium–glucose cotransporter 2 (SGLT-2) inhibitors , may be appropriate for some adults with type 2 diabetes if metformin is contraindicated or not tolerated (see NICE's guidance on canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes).	In adults with type 2 diabetes, if initial drug treatment with metformin has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider dual therapy with: metformin and a DPP-4 inhibitor or metformin and pioglitazone or metformin and a sulfonylurea.	In adults with type 2 diabetes, if metformin is contraindicated or not tolerated and initial drug treatment has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider dual therapy with: a DPP-4 inhibitor and pioglitazone or a DPP-4 inhibitor and a sulfonylurea or pioglitazone and a sulfonylurea.	Treatment with combinations of medicines including sodium–glucose cotransporter 2 (SGLT-2) inhibitors , may be appropriate for some people with type 2 diabetes; see the NICE guidance on canagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in combination therapy for treating type 2 diabetes and empagliflozin in combination therapy for treating type 2 diabetes.	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation ) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations – ).	If triple therapy with metformin and 2 other oral drugs (see recommendation ) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities.	In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, and if dual therapy with 2 oral drugs (see recommendation ) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider insulin-based treatment (see recommendations – ).	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	In adults with type 2 diabetes, only offer a GLP-1 mimetic in combination with insulin with specialist care advice and ongoing support from a consultant-led multidisciplinary team .	Treatment with combinations of medicines including SGLT-2 inhibitors , may be appropriate for some people with type 2 diabetes; see the NICE guidance on canagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in triple therapy for treating type 2 diabetes and empagliflozin in combination therapy for treating type 2 diabetes.	When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding	When starting insulin therapy in adults with type 2 diabetes, continue to offer metformin for people without contraindications or intolerance	Start insulin therapy for adults with type 2 diabetes from a choice of a number of insulin types and regimens:	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Consider switching to insulin detemir or insulin glargine from NPH insulin in adults with type 2 diabetes: who do not reach their target HbA1c because of significant hypoglycaemia or who experience significant hypoglycaemia on NPH insulin irrespective of the level of	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Monitor adults with type 2 diabetes who are on a basal insulin regimen (NPH insulin, insulin detemir or insulin glargine ) for the need for short-acting insulin before meals (or a pre-mixed biphasic insulin preparation).	Monitor adults with type 2 diabetes who are on pre-mixed (biphasic) insulin for the need for a further injection of short-acting insulin before meals or for a change to a basal bolus regimen with NPH insulin or insulin detemir or insulin glargine , if blood glucose control remains inadequate.	Treatment with combinations of medicines including SGLT-2 inhibitors , may be appropriate for some people with type 2 diabetes; see the NICE guidance on canagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in combination therapy for treating type 2 diabetes and empagliflozin in combination therapy for treating type 2 diabetes.	For guidance on insulin delivery for adults with type 2 diabetes, see the insulin delivery section in the NICE guideline on type 1 diabetes.	Think about a diagnosis of gastroparesis in adults with type 2 diabetes with erratic blood glucose control or unexplained gastric bloating or vomiting, taking into account possible alternative diagnoses 2009, amended 2015	For adults with type 2 diabetes who have vomiting caused by gastroparesis, explain that: there is not strong evidence that any available antiemetic therapy is effective some people have had benefit with domperidone , erythromycin or metoclopramide . the strongest evidence for effectiveness is for domperidone , but prescribers must	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	For treating vomiting caused by gastroparesis in adults with type 2 diabetes: consider alternating use of erythomycin and metoclopramide consider domperidone only in exceptional circumstances (if domperidone is the only effective treatment) and in accordance with MHRA guidance.	For guidance on managing painful diabetic peripheral neuropathy in adults with type 2 diabetes, see the NICE guideline on neuropathic pain in adults.	Think about the possibility of contributory sympathetic nervous system damage for adults with type 2 diabetes who lose the warning signs of hypoglycaemia. 2009, amended 2015	Think about the possibility of autonomic neuropathy affecting the gut in adults with type 2 diabetes who have unexplained diarrhoea that happens particularly at night 2009, amended 2015	When using tricyclic drugs and antihypertensive drug treatments in adults with type 2 diabetes who have autonomic neuropathy, be aware of the increased likelihood of side effects such as orthostatic hypotension.	Investigate the possibility of autonomic neuropathy affecting the bladder in adults with type 2 diabetes who have unexplained bladder-emptying problems.	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	For guidance on preventing and managing foot problems in adults with type 2 diabetes, see the NICE guideline on diabetic foot problems.	For guidance on managing kidney disease in adults with type 2 diabetes, see the	Offer men with type 2 diabetes the opportunity to discuss erectile dysfunction as part of their annual review.	Assess, educate and support men with type 2 diabetes who have problematic erectile dysfunction, addressing contributory factors such as cardiovascular disease as well as possible treatment options.	Consider a phosphodiesterase-5 inhibitor to treat problematic erectile dysfunction in men with type 2 diabetes, initially choosing the drug with the lowest acquisition cost and taking into account any contraindications.	Following discussion, refer men with type 2 diabetes to a service offering other medical, surgical or psychological management of erectile dysfunction if treatment (including a phosphodiesterase-5 inhibitor, as appropriate) has been unsuccessful.	On diagnosis, GPs should immediately refer adults with type 2 diabetes to the local eye screening service	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Explain the reasons for, and success of, eye screening systems to adults with type 2 diabetes, so that attendance is not reduced by lack of knowledge or fear of outcome.	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Be aware that, if metformin is contraindicated or not tolerated, repaglinide is both clinically effective and cost effective in adults with type 2 diabetes	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	
